Document:

Exhibit 10.13

 Exhibit 10.13 
 REDACTED COPY 
 CONFIDENTIAL 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act
of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the
“Agreement”) is made and entered into effective as of April 27, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with
offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and SOLIGENIX, INC., a Delaware corporation having a place of business at 29 Emmons Drive, Suite C-10, Princeton, NJ
08540 (“Soligenix”). Intrexon and Soligenix may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 
 WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and
DNA vectors, and the control of peptide expression; and 
 WHEREAS, Soligenix now desires to become
Intrexon’s exclusive channel collaborator with respect to such technology for the purpose of developing the Melioidosis Program (as defined herein), and Intrexon is willing to appoint Soligenix as a channel collaborator in the Field (as defined
herein, and subject to amendments to the definition as permitted herein) under the terms and conditions of this Agreement. 

NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained herein,
the Parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 As used in this Agreement, the following
capitalized terms shall have the following meanings: 
 1.1 “Affiliate” means, with respect to a
particular Party, any other person or entity that directly or indirectly controls, is controlled by, or is in common control with such Party. As used in this Section 1.1, the term “controls” (with correlative meanings for the terms
“controlled by” and “under common control with”) means the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of an entity, or the possession, directly or
indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, Third Security shall be deemed not to be an Affiliate of
Intrexon, and neither Party shall be deemed to be an Affiliate of the other Party. In addition, any other person, corporation, partnership, or other entity that would be an Affiliate of Intrexon solely because it and Intrexon are under common
control by Randal J. Kirk or by investment funds managed by Third Security or an affiliate of Third Security shall also be deemed not to be an Affiliate of Intrexon. 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.2 “Applicable Laws” has the meaning set forth in
Section 8.2(e)(xii). 
 1.3 “Authorizations” has the meaning set forth in Section 8.2(e)(xii).

 1.4 “Biodefense” means procedures involved in taking defensive measures against attacks using
biological agents, which includes without limitation emerging pathogen threats. 
 1.5 “Biodefense
Sector” means government agencies including but not limited to the Department of Defense (“DoD”), Department of Health and Human Services (“DHHS”), Department of Homeland Security (“DHS”), Biomedical Advanced
Research and Development Authority (“BARDA”), and the Centers for Disease Control and Prevention (“CDC”). 

1.6 “CC” has the meaning set forth in Section 2.2(b). 

1.7 “Channel-Related Program IP” has the meaning set forth in Section 6.1(c). 

1.8 “Claims” has the meaning set forth in Section 9.1. 

1.9 “CMCC” has the meaning set forth in Section 2.2(b). 

1.10 “Committees” has the meaning set forth in Section 2.2(a). 

1.11 “Commercialize” or “Commercialization” means any activities directed to marketing,
promoting, distributing, importing for sale, offering to sell and/or selling Soligenix Products. 
 1.12
“Commercial Sale” means for a given product and country the sale for value of that product by a Party (or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval (if
necessary) has been obtained for such product in such country. 
 1.13 “Complementary In-Licensed Third Party
IP” has the meaning set forth in Section 3.8(a). 
 1.14 “Confidential Information” means
each Party’s confidential Information disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties, regardless of whether in oral, written, graphic or electronic form. 

1.15 “Control” means, with respect to Information, a Patent or other intellectual property right, that a Party
owns or has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right without violating the terms of any agreement or other arrangement with any Third Party.

 1.16 “Diligent Efforts” means, with respect to a Party’s obligation under this Agreement, the
level of efforts and resources reasonably required to diligently develop, 

  
 2 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
manufacture, and/or Commercialize (as applicable) each Soligenix Product in a sustained manner, consistent with the efforts and resources a similarly situated company working in the Field would
typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to a particular task or obligation, Diligent Efforts requires that
the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such task or obligation. 

1.17 “Emergency Use Authorization” or “EUA” means an authorization by the FDA under section 564
of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 360bbb-3) whereby certain unapproved medical products or unapproved uses of approved medical products may nonetheless be used in an emergency to diagnose, treat, or prevent serious
or life-threatening diseases or conditions caused by biologic, chemical, or nuclear agents when there are no adequate approved and available alternatives. 
 1.18 “Equity Agreement” has the meaning set forth in Section 5.1. 
 1.19 “Excess Product Liability Costs” has the meaning set forth in Section 9.3. 
 1.20 “Executive Officer” means : (a) the Chief Executive Officer of the applicable Party, or (b) another senior executive officer of such Party who has been duly
appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (i) a Committee dispute, provided that such appointed officer is not a member of the applicable Committee and occupies a position
senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (ii) a dispute described in Section 11.1. 
 1.21 “FDA” has the meaning set forth in Section 8.2(e)(xii). 
 1.22 “Field” means exogenously produced human recombinant monoclonal antibodies, and mixes of such antibodies, for use in the prevention or treatment of Melioidosis in humans.

 1.23 “Field Infringement” has the meaning set forth in Section 6.3(b). 

1.24 “Fully Loaded Cost” means the direct cost of the applicable good, product or service plus indirect charges
and overheads reasonably allocable to the provision of such good, product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC and the terms of Sections 4.6 and 4.7 (as appropriate),
Intrexon will bill for its internal direct costs incurred through the use of annualized standard full-time equivalents; such rate shall be based upon the actual fully loaded costs of those personnel directly involved in the provision of such good,
product or service. Intrexon may, from time to time, adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will review the accuracy of its full-time equivalent rate at least quarterly. Intrexon shall provide
Soligenix with reasonable documentation indicating the basis for any direct and indirect charges, any allocable overhead, and any such adjustment in full-time equivalent rate. 

  
 3 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.25 “Government Funding” means use of grants, contracts or other
mechanisms from government agencies, including but not limited to the DHHS, BARDA, and DoD to fund development activities in the Field. 
 1.26 “In-Licensed Program IP” has the meaning set forth in Section 3.8(a). 
 1.27 “Information” means information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, business information and
plans (such as marketing, financial, and personnel), manufacturing information and data, technical information, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience,
test data including pharmacological, biological, chemical, biochemical, toxicological and regulatory test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions.

 1.28 “Infringement” has the meaning set forth in Section 6.3(a). 

1.29 “Intrexon Channel Technology” means Intrexon’s current and future technology
directed towards the design, identification, culturing, and/or production of genetically modified cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and specifically including without
limitation the following of Intrexon’s platform areas and capabilities: (1) UltraVector®,
(2) LEAPTM, (3) DNA and RNA MOD engineering,
(4) protein engineering, (5) transcription control chemistry, (6) genome engineering, and (7) cell system engineering. 
 1.30 “Intrexon Indemnitees” has the meaning set forth in Section 9.2. 
 1.31 “Intrexon IP” means the Intrexon Patents and Intrexon Know-How. 
 1.32 “Intrexon Know-How” means all Information (other than Intrexon Patents) that (a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is
reasonably required or useful for Soligenix to conduct the Melioidosis Program. For the avoidance of doubt, the Intrexon Know-How shall include any Information (other than Intrexon Patents) in the Channel-Related Program IP. 

1.33 “Intrexon Materials” means the genetic code and associated amino acids and gene constructs, in each case
that are Controlled by Intrexon, used alone or in combination and such other proprietary reagents and biological materials including but not limited to plasmid vectors, virus stocks, cells and cell lines, antibodies, and ligand-related chemistry, in
each case that are provided to Soligenix by or on behalf of Intrexon to conduct the Melioidosis Program. 
 1.34
“Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the Effective Date or during the Term; and (b) are reasonably required or useful for Soligenix to conduct the Melioidosis Program. For the
avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP. 

  
 4 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.35 “Intrexon Trademarks” means those trademarks related to the
Intrexon Channel Technology that are established from time to time by Intrexon for use across its channel partnerships or collaborations. 
 1.36 “Inventions” has the meaning set forth in Section 6.1(b). 
 1.37 “IPC” has the meaning set forth in Section 2.2(b). 
 1.38 “JSC” has the meaning set forth in Section 2.2(b). 
 1.39 “Losses” has the meaning set forth in Section 9.1. 
 1.40 “Melioidosis” means a potentially fatal infection caused by the Gram-negative bacilli, Burkholderia pseudomallei and the closely-related B. mallei. 

1.41 “Melioidosis Program” has the meaning set forth in Section 2.1(a). 

1.42 “Net Sales” means, with respect to any Soligenix Product, the net sales of such Soligenix Product by
Soligenix, an Affiliate of Soligenix, or a Product Sublicensee, as determined in accordance with US GAAP as the gross amount invoiced on account of sales of Soligenix Product less the usual and customary credits, discounts and the like as
determined in accordance with US GAAP. In the case of any sale for value, such as barter or counter-trade other than in an arm’s length transaction exclusively for cash, Net Sales shall be deemed to be the net sales at which substantially
similar quantities of the product are sold for cash in an arm’s length transaction in the relevant country. If Soligenix Product is sold by Soligenix, its Product Sublicense, or Affiliates thereof to any Third Party together with other products
or services, the price of such product, solely for purposes of the calculation of Net Sales, shall be deemed to be no less than the price at which such product would be sold in a similar transaction to a Third Party not also purchasing the other
products or services. 
 1.43 “Patents” means (a) all patents and patent applications (including
provisional applications), (b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for continued examination, confirmations, re-examinations, extensions, supplementary protection
certificates and the like of the foregoing, and (c) any foreign or international equivalents of any of the foregoing. 

1.44 “Product-Specific Program Patent” means any issued Intrexon Patent where all the claims are directed to
Inventions that relate solely and specifically to Soligenix Products or their use in the Field. In the event of a disagreement between the Parties as to whether a particular Intrexon Patent is or is not a Product-Specific Program Patent, the Parties
shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration pursuant to Section 11.2. Any Intrexon Patent that is subject to
such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or (b) an arbitrator or arbitration panel determines, pursuant
to Article 11, that such Intrexon Patent is a Product-Specific Program Patent. 

  
 5 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.45 “Product Sublicense” has the meaning set forth in
Section 3.2(c). 
 1.46 “Product Sublicensee” has the meaning set forth in Section 3.2(c).

 1.47 “Proposed Terms” has the meaning set forth in Section 11.2. 

1.48 “Prosecuting Party” has the meaning set forth in Section 6.2(c). 

1.49 “RC” has the meaning set forth in Section 2.2(b). 

1.50 “Recovery” has the meaning set forth in Section 6.3(f). 

1.51 “Regulatory Trial” means any clinical or preclinical studies or trials done to produce data intended for or
useful for any requisite government approvals for the sale, use, or manufacture of a relevant product. 
 1.52
“Retained Product” has the meaning set forth in Section 10.4(a). 
 1.53 “Reverted
Product” has the meaning set forth in Section 10.4(c). 
 1.54 “SEC” means the United
States Securities and Exchange Commission. 
 1.55 “Soligenix Indemnitees” has the meaning set forth in
Section 9.1. 
 1.56 “Soligenix Independent IP” has the meaning set forth in Section 6.1(f).

 1.57 “Soligenix Product” means any product in the Field that is created, produced, developed, or
identified in whole or in part, directly or indirectly, by or on behalf of Soligenix (including without limitation by Intrexon under the Melioidosis Program), its Product Sublicensee(s), or Affliliates thereof during the Term through use or practice
of Intrexon Channel Technology, Intrexon IP, or the Intrexon Materials. 
 1.58 “Soligenix Program
Patent” has the meaning set forth in Section 6.2(b). 
 1.59 “Soligenix Termination IP”
means all Patents, regulatory data rights, or other intellectual property that Soligenix or any of its Affiliates Controls as of the Effective Date or during the Term that cover, or is otherwise necessary or useful for, the development, manufacture
or Commercialization of a Reverted Product or necessary or useful for Intrexon to operate in the Field. Notwithstanding the foregoing, Soligenix Termination IP shall not include Soligenix Independent IP. 

1.60 “Sublicensing Revenue” means any cash consideration, or the cash equivalent value of non-cash consideration,
regardless of whether in the form of upfront payments, 

  
 6 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
milestones, or royalties, actually received by Soligenix or its Affiliate from a Third Party in consideration for a grant of a sublicense under the Intrexon IP or any rights to develop or
Commercialize Soligenix Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent incurred following such grant; (b) bona fide loans or any payments in consideration for a
grant of equity of Soligenix to the extent that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing Revenue); (c) any amounts received from sublicensees in respect
of any Soligenix Product sales that are included in the calculation of revenue sharing payments made to Intrexon under Section 5.4(a); (d) any amounts paid by Soligenix to a Third Party for the right to operate under or utilize Third Party
owned intellectual property that is used to make or use a Soligenix Product underlying the Sublicensing Revenue; and (e) subject to the waiver provisions of Section 5.2, any payments received by Soligenix from Product Sublicensees for the
attainment of a milestone event that is the same as (or substantially similar to) a milestone event for which Intrexon is entitled to receive a milestone payment under Section 5.2. 

1.61 “Superior Therapy” means a therapy in the Field and licensed to Soligenix under this Agreement that, based
on the data then available, (a) demonstrably appears to offer either superior efficacy or safety or significantly lower cost of therapy, as compared with both (i) those therapies that are marketed (either by Soligenix or others) at such
time for the indication and (ii) those therapies that are being actively developed by Soligenix for such indication; (b) demonstrably appears to represent a substantial improvement over such existing therapies; and (c) has
intellectual property protection and a regulatory approval pathway that, in each case, would not present a significant barrier to commercial development. 
 1.62 “Supplemental In-Licensed Third Party IP” has the meaning set forth in Section 3.8(a). 
 1.63 “Support Memorandum” has the meaning set forth in Section 11.2. 
 1.64 “Technology Access Fee” for the purposes of this Agreement has the meaning as set forth in Section 5.1. 

1.65 “Term” has the meaning set forth in Section 10.1. 

1.66 “Territory” means the world. 
 1.67 “Third Party” means any individual or entity other than the Parties or their respective Affiliates. 
 1.68 “Third Security” means Third Security, LLC. 
 1.69
“US GAAP” means generally accepted accounting principles in the United States. 

  
 7 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 2 
 SCOPE OF CHANNEL COLLABORATION; MANAGEMENT 
 2.1 Scope. 
 (a) Generally. The general purpose of the channel
collaboration described in this Agreement will be to use the Intrexon Channel Technology to research, develop and Commercialize products for use in the Field (collectively, the “Melioidosis Program”). As provided below, the JSC
shall establish, monitor, and govern projects for the Melioidosis Program. Either Party may propose potential projects in the Field for review and consideration by the JSC. Intrexon recognizes that Soligenix’s intention is for the Melioidosis
Program to be supported predominantly by Government Funding through the Biodefense Sector and/or by non-profit agencies as an emerging infectious disease. Therefore, the JSC shall prioritize and account for such funding mechanisms in progressing the
Melioidiosis Program consistent with the rights and obligations of the Parties as set forth herein. 
 2.2 Committees.

 (a) Generally. The Parties desire to establish several committees (collectively, “Committees”) to
oversee the Melioidosis Program and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the
obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. 
 (b) Formation and Purpose. Promptly following the Effective Date, the Parties shall confer and then create the JSC and the IPC, and, optionally, create one or more of the other Committees listed in
the chart below. Each Committee shall have the purpose indicated in the chart. To the extent that after conferring both Parties agree to not create a Committee (other than the JSC and the IPC), the creation of such Committee shall be deferred until
one Party informs the other Party of its then desire to create the so-deferred Committee, at which point the Parties will thereafter promptly create the so-deferred Committee. 

 

			
	 Committee
	  	 Purpose

	Joint Steering Committee (“JSC”)	  	Establish projects for the Melioidosis Program and establish the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and plans (except for
decisions of the IPC). The JSC shall establish budgets not less than on a quarterly basis.
		
	Chemistry, Manufacturing and Controls Committee (“CMCC”)	  	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Melioidosis
Program.

  
 8 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

			
	 Committee
	  	 Purpose

	Regulatory Committee (“RC”)	  	Review and approve all research and development plans and projects, including but not limited to clinical projects, associated with any necessary regulatory approvals, all
associated publications, and all regulatory filings and correspondence relating to gaining regulatory approval for new Soligenix Products under the Melioidosis Program; and review and approve itemized budgets with respect to the
foregoing.
		
	Commercialization Committee (“CC”)	  	Establish project plans and review and approve activities and budgets for Commercialization activities under the Melioidosis Program.
		
	Intellectual Property Committee (“IPC”)	  	Evaluate all intellectual property issues in connection with the Melioidosis Program; review and approve itemized budgets with respect to the foregoing.

 2.3 General Committee Membership and Procedure. 

(a) Membership. For each Committee, each Party shall designate an equal number of representatives (not to exceed three
(3) for each Party) with appropriate expertise to serve as members of such Committee. For the JSC, the representatives must all be employees of such Party or an Affiliate of such Party. For Committees other than the JSC, the representatives
must all be employees of such Party or an Affiliate of such Party, with the caveat that each Party may designate for each such other Committee up to one (1) representative who is not an employee if : (i) such non-employee representative
agrees in writing to be bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (ii) the other Party consents to the designation of such non-employee representative,
which consent shall not be unreasonably withheld. For purposes of this Section 2.3, employees of Third Security may, at Intrexon’s election, serve as members of a Committee as if they were employees of Intrexon; provided that they meet the
requirement of clause (i) above. Each representative as qualified above may serve on more than one (1) Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any time
upon written notice to the other Party. Each Committee shall have a 

  
 9 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee will act as chairperson shall alternate between the
Parties, with Soligenix selecting the chairperson first for the JSC, RC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall be responsible for calling meetings, preparing and circulating
an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. 
 (b) Meetings. The JSC shall be constituted and the first meeting of the JSC shall be held promptly following the Effective Date, with the JSC considering finalization and approval of workplans
prepared by the Parties for inclusion and commencement under the Melioidosis Program. Otherwise, each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less frequently than once every six
(6) months, with the caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other Party of its then desire to reactivate the so-suspended Committee, at which
point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any Committee may be held in person or by means of telecommunication (telephone, video, or web conferences). To
the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Soligenix selecting the first meeting location for each Committee. A reasonable number of additional
representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee excepting that an Intrexon employee or agent serving on a Committee
shall not prevent Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of providing manufacturing or support services as set forth in Sections 4.6 and 4.7 below. 

(c) Meeting Agendas. Each Party will disclose to the other proposed agenda items along with appropriate information at least three
(3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a
specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee meeting. 

(d) Limitations of Committee Powers. Each Committee shall have only such powers as are specifically delegated to it hereunder or
from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have any power to amend this Agreement.
Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. 
 2.4
Committee Decision-Making. If a Committee is unable to reach unanimous consent on a particular matter within thirty (30) days of its initial consideration of such matter, 

  
 10 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
then either Party may provide written notice of such dispute to the Executive Officer of the other Party. The Executive Officers of each of the Parties will meet at least once in person or by
means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such
dispute is not resolved by the Executive Officers within thirty (30) days after submission of such dispute to such Executive Officers, then the Executive Officer of the Party specified in the applicable subsection below shall have the authority
to finally resolve such dispute acting in good faith. 
 (a) Casting Vote at JSC. If a dispute at the JSC is not resolved
pursuant to Section 2.4 above, then the Executive Officer of Soligenix shall have the authority to finally resolve such dispute. 
 (b) Casting Vote at CMCC. If a dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i) in the case of any disputes relating to the Intrexon Materials, the manufacture
of a Soligenix Product through the use of Intrexon Channel Technology or Intrexon IP, or the manufacturing of other components of Soligenix Products contracted for or manufactured by Intrexon or reasonable controls regarding the dissemination of
Intrexon Technology, Intrexon IP or Intrexon Materials, the Executive Officer of Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of any other disputes, the Executive Officer of Soligenix shall have the
authority to finally resolve such dispute. 
 (c) Casting Vote at RC. If a dispute at the RC is not resolved pursuant to
Section 2.4 above, then the Executive Officer of Soligenix shall have the authority to finally resolve such dispute. 

(d) Casting Vote at CC. If a dispute at the CC is not resolved pursuant to Section 2.4 above, then the Executive Officer of
Soligenix shall have the authority to finally resolve such dispute. 
 (e) Casting Vote at IPC. If a dispute at the IPC
is not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the Parties with respect to Product-Specific Program
Patents (i.e., neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11). 
 (f) Other Committees. If any additional Committee or subcommittee other than those set forth in Section 2.2(b) is formed, then the Parties shall, at the time of such formation, agree on which
Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above. 
 (g)
Restrictions. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this
Agreement; (ii) expands the 

  
 11 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
obligations of the other Party under this Agreement; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to
resolve any dispute involving the breach or alleged breach of this Agreement; (v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to
perform any act that is inconsistent with applicable law. 
 ARTICLE 3 

LICENSE GRANTS 
 3.1 Licenses to Soligenix. 
 (a) Subject to the terms and conditions
of this Agreement, Intrexon hereby grants to Soligenix a license under the Intrexon IP to research, develop, use, make, have made, sell, offer for sale, import and export Soligenix Products in the Field in the Territory. Such license shall be
exclusive (even as to Intrexon) with respect to any development, selling, offering for sale or other Commercialization of Soligenix Products in the Field, and shall be otherwise non-exclusive. 

(b) Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Soligenix a non-exclusive, royalty-free
license to use and display the Intrexon Trademarks, solely in connection with the Commercialization of Soligenix Products in the promotional materials, packaging, and labeling for Soligenix Products, as provided under and in accordance with
Section 4.9. 
 3.2 Sublicensing. Except as provided in this Section 3.2, Soligenix shall not sublicense the
rights granted under Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or Commercialize Soligenix Products or use or display the
Intrexon Trademarks, in each case except with Intrexon’s written consent, which written consent may be withheld in Intrexon’s sole discretion. Notwithstanding the foregoing, Soligenix (and its Product Sublicensees only to the extent
explicitly set forth in Section 3.2(a) beow) shall have a limited right to sublicense under the circumstances described in Sections 3.2(a) through 3.2(c). 
 (a) Soligenix may transfer, to the extent reasonably necessary, Intrexon Materials that are or express Soligenix Products to a Third Party contractor performing contract manufacturing, fill, and/or
finish responsibilities for Soligenix Products, and may in connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If Soligenix transfers any Intrexon Materials under this Section 3.2(a),
Soligenix will remain obligated to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any such Third Party contractor. A Product
Sublicensee of Soligenix may transfer, to the extent reasonably necessary and upon the consent of Intrexon, which consent shall not be unreasonably withheld, Intrexon Materials that are or express active pharmaceutical ingredients to a Third

  
 12 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Party contractor performing fill/finish responsibilities for Soligenix Products duly sublicensed to that Product Sublicensee, and may in connection therewith grant limited sublicenses to the
extent necessary to enable such Third Party to perform such activities. Soligenix will require and ensure that if any Product Sublicensee transfers any Intrexon Materials under this Section 3.2(a), that such Product Sublicensee, after obtaining
Intrexon’s consent, and Soligenix will be responsible for ensuring that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any such Third
Party contractor. 
 (b) Soligenix may, with Intrexon’s written consent, which consent shall not be unreasonably
withheld, sublicense the rights granted under Section 3.1 to an Affiliate, or transfer the Intrexon Materials to an Affiliate, or grant an Affiliate the right to display the Intrexon Trademarks. In the event that Intrexon consents to any such
grant or transfer to an Affiliate, Soligenix shall remain responsible for, and be guarantor of, the performance by any such Affiliate and shall cause such Affiliate to comply with the provisions of this Agreement in connection with such performance
(as though such Affiliate were Soligenix), including any payment obligations owed to Intrexon hereunder. 
 (c) Soligenix
may, with Intrexon’s written consent, which consent may not be unreasonably withheld, grant a sublicense of the rights granted under Section 3.1 to a Third Party licensee of any Soligenix Product (a “Product Sublicensee”)
to the extent necessary to permit such Third Party to research, develop, use, import, export, make, sell, and offer for sale that Soligenix Product (a “Product Sublicense”), provided, that (i) the Soligenix Product in question
has completed a Phase I clinical trial, (ii) such Product Sublicense is expressly limited to the appropriate Soligenix Product, (ii) such Product Sublicense does not grant the Product Sublicensee any rights to Intrexon IP other than that
incorporated into the Soligenix Product at the time of the Product Sublicense, (iii) such Product Sublicense does not purport to relieve Soligenix of any of its obligations under this Agreement, (iv) the Product Sublicensee agrees in
writing, in a document in form reasonably acceptable to Intrexon and to which Intrexon is an express third party beneficiary, to abide by the following provisions of this Agreement: Sections 3.1, 3.2(a), 3.3-3.6, 3.8, 3.10, 3.11, and 4.6 and
Articles 6, 7, and 10, and (v) the Product Sublicense is presented in full to the JSC and IPC by Soligenix before execution by Soligenix and the prospective Product Sublicensee and as soon as is reasonably practical during negotiations thereof
for the purpose of allowing the JSC and IPC to review and comment upon the terms and scope of the Product Sublicense agreement. 

3.3 Limitation on Sublicensees. None of the enforcement rights under the Intrexon Patents that are granted to Soligenix pursuant
to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior written consent, which may be withheld in Intrexon’s sole discretion. 

3.4 No Non-Permitted Use. Soligenix hereby covenants that it shall not, nor shall it permit any Affiliate or, if applicable,
(sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly permitted by this Agreement. 

  
 13 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 3.5 Exclusivity. Intrexon and Soligenix mutually agree that, under the channel
collaboration established by this Agreement, it is intended that the Parties will be exclusive to each other in the Field as set forth in this Section 3.5. Neither Intrexon nor its Affiliates shall make the Intrexon Channel Technology or
Intrexon Materials available to any Third Party for the purpose of developing or Commercializing products in the Field (except as set forth in Section 3.2), and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third
Party or Affiliate) the research, development or Commercialization of any product for purpose of commercial use or sale in the Field, outside of the Melioidosis Program. Further, neither Soligenix nor its Affiliates shall pursue (either by itself or
with a Third Party or Affiliate) outside of the Melioidosis Program the research, development or Commercialization of any product for purpose of commercial use or sale in the Field where such products would compete with Soligenix Products.

 3.6 Off Label Use. For purpose of clarity, (a) following first Commercial Sale of a Soligenix Product, the use by
direct or indirect purchasers or other users of Soligenix Products outside the Field (i.e. “off label use”) shall not constitute a breach by Soligenix of the terms of Section 3.4 or 3.5, provided that neither Soligenix nor its
Affiliate (nor any Third Party under contract with either of them) marketed or promoted Soligenix Products for such off-label use; and (b) following first Commercial Sale of a product by Intrexon, an Intrexon Affiliate, or a Third Party
sublicensee, collaborator, or partner of Intrexon, the use by direct or indirect purchasers or other users of such products in the Field (i.e. “off label use”) shall not constitute a breach by Intrexon of the terms of Section 3.5,
provided that neither Intrexon nor its Affiliate (nor any Third Party under contract with either of them) marketed or promoted such products for such off-label use. 
 3.7 No Prohibition on Intrexon. Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this Agreement shall prevent Intrexon from practicing or using the Intrexon Materials, Intrexon
Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, Soligenix acknowledges that Intrexon has all rights, in Intrexon’s sole discretion,
to use or make the Intrexon Materials, Intrexon Channel Technology (including any genetic materials used in a Soligenix Product), and Intrexon IP available to Third Party channel partners or collaborators for use in fields outside the Field.

 3.8 Rights to Regulatory Data. 
 (a) Soligenix shall own and control all Regulatory Trial data and regulatory filings relating to Commercialization of Soligenix Products (except to the extent such become Reverted Products).

  
 14 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (b) Soligenix shall provide to Intrexon at Intrexon’s request full copies of
all Regulatory Trial data and reports, regulatory filings, and communications from regulatory authorities that relate specifically and solely to Soligenix Products. To the extent that there exist any Regulatory Trial data and reports, regulatory
filings, and communications from regulatory authorities owned by Soligenix or a Product Sublicensee that relate both to Soligenix Products and other products produced by Soligenix or a Product Sublicensee outside the Field or outside the Melioidosis
Program, upon Intrexon’s request Soligenix shall provide (or require that the Product Sublicensee provide) to Intrexon copies of the portions of such data, reports, filings, and communications that relate to Soligenix Products. Subject to its
ongoing obligations of exclusivity under Section 3.5, Intrexon shall be permitted, directly or in conjunction with or through partners or other channel collaborators, to reference these data, reports, filings, and communications relating to
Soligenix Products in regulatory filings made to obtain regulatory approval for products for use in fields outside the Field. Intrexon shall have the right to use any such information in developing and Commercializing products outside the Field and
to license any Third Parties to do so. Notwithstanding the provisions of this Section 3.8, Intrexon shall not, outside of the Melioidosis Program, utilize any Soligenix or Product Sublicensee data, reports, filings or communications for any
reason in the Field. 
 (c) Intrexon shall provide to Soligenix at Soligenix’s request full copies of all Regulatory
Trial data and reports, regulatory filings, and communications from regulatory authorities that relate specifically and solely to Intrexon Materials incorporated in a Soligenix Product or products incorporating such Intrexon Materials. To the extent
that there exist any Regulatory Trial data and reports, regulatory filings, and communications from regulatory authorities owned by Intexon or partners or other channel collaborators that relate both to such Intrexon Materials or products and other
products produced by Intrexon or a partner or other channel collaborator, upon Soligenix’s request Intrexon shall provide (or use reasonable efforts to cause Intrexon’s partner or other channel collaborator provide) to Soligenix copies of
the portions of such data, reports, filings, and communications that relate to such Intrexon Materials or products. Subject to its ongoing obligations of exclusivity under Section 3.5, Soligenix shall be permitted, directly or in conjunction
with Product Sublicensees, to reference these data, reports, filings, and communications relating to such Intrexon Materials or Products in regulatory filings made to obtain regulatory approval for Soligenix Products in the Field. Soligenix shall
have the right to use any such information in developing and Commercializing Soligenix Products in the Field and, subject to Section 3.2 to license any Product Sublicensees to do so. Notwithstanding the provisions of this Section 3.8,
Soligenix shall not utilize any data, reports, filings or communications obtained under this Section 3.8(c) for any reason other than for development and Commercialization of Soligenix Products. 

3.9 Third Party Licenses. 
 (a) [*****] shall obtain [*****] any licenses from Third Parties that are required in order to practice the Intrexon Channel Technology in the Field where the licensed intellectual property is
reasonably necessary for Intrexon to conduct genetic and cell engineering and related analytic activities under JSC established plans for the Melioidosis Program (but 

  
 15 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
specifically excluding intellectual property directed to any specific antibodies, methods of treatment or therapy, cell lines, active pharmaceutical ingredients, delivery or packaging methods or
apparatuses, or processes or methods for commercially manufacturing Soligenix Products) (“Supplemental In-Licensed Third Party IP”). Other than with respect to Supplemental In-Licensed Third Party IP, [*****] shall be solely
responsible for obtaining [*****] any licenses from Third Parties that [*****] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or import Soligenix Products (“Complementary In-Licensed
Third Party IP”). Supplemental In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively referred to as “In-Licensed Program IP”. 

(b) In the event that either Party desires to license from a Third Party any Supplemental In-Licensed Third Party IP or
Complementary In-Licensed Third Party IP, such Party shall so notify the other Party, and the IPC shall discuss such In-Licensed Program IP and its applicability to the Soligenix Products and to the Field. As provided above in Section 3.8(a),
[*****] shall have the sole right and responsibility to pursue a license under Supplemental In-Licensed Third Party IP, and [*****] hereby covenants that it shall not itself directly license such Supplemental In-Licensed Third Party IP at any time,
provided that [*****] may (but shall not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Supplemental In-Licensed Third Party IP brings an infringement action against [*****] or its
Affiliates or threatens to bring such action (to the extent such threats would reasonably be considered to subject the Third Party owner or licensee to declaratory judgment jurisdiction) and, after written notice to [*****] of such action, [*****]
fails to obtain a license to such Supplemental In-Licensed Third Party IP using Diligent Efforts within ninety (90) days after such notice. Following the IPC’s discussion of any Complementary In-Licensed Third Party IP, subject to
Section 3.8(c), [*****] shall have the right to pursue a license under Complementary In-Licensed Third Party IP [*****]. For the avoidance of doubt, [*****] may at any time obtain a license under Complementary In-Licensed Third Party IP outside
the Field [*****] provided that if [*****] decides to seek to obtain such a license, it shall use reasonable efforts to coordinate its licensing activities in this regard with [*****]. 

(c) [*****] shall provide the proposed terms of any license under Complementary In-Licensed Third Party IP and the final version
of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and discussion prior to signing, and shall consider [*****] comments thereto in good faith. To the extent that [*****] obtains a license under
Supplemental In-Licensed Third Party IP, [*****] shall provide the final version of the definitive license agreement for such Supplemental In-Licensed Third Party IP to the IPC. If [*****] acquires rights under any In-Licensed Program IP outside the
Field, it will do so on a non-exclusive basis unless it obtains the prior written consent of [*****] for such license outside the Field to be exclusive. Any Party that is pursuing a license to any In-Licensed Program IP with respect to the Field
under this Section 3.8 shall keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of clarity, (i) any costs incurred by [*****] in obtaining and maintaining licenses to Supplemental
In-Licensed Third Party IP shall be borne solely by [*****], and (ii) any costs incurred by [*****] in obtaining and maintaining licenses to Complementary In-Licensed Third Party IP (and, to the limited extent provided in subsection (b),
Supplemental In-Licensed Third Party IP) shall be borne solely by [*****]. 

  
 16 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (d) For any Third Party license under which Soligenix or its Affiliates obtain a
license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture, and/or Commercialization of Soligenix Products, Soligenix shall use commercially reasonable efforts to ensure that Soligenix
will have the ability, pursuant to Section 10.4(h), to assign such agreement to Intrexon or grant a sublicense to Intrexon thereunder (having the scope set forth in Section 10.4(h)). 

(e) The licenses granted to Soligenix under Section 3.1 may include sublicenses under Intrexon IP that has been licensed to
Intrexon by one or more Third Parties. All such sublicenses are subject to the terms and conditions set forth in the applicable upstream license agreement, subject to the cost allocation set forth in Section 3.8(c), provided that
Intrexon shall either provide unredacted copies of such upstream license agreements to Soligenix or shall disclose in writing to Soligenix all of such terms and conditions that are applicable to Soligenix. Soligenix shall not be responsible for
complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to Soligenix as provided in the preceding sentence. 

(f) If either Party receives notice from a Third Party concerning activities of a Party taken in conjunction with performance of
obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the receiving Party shall inform the other party
thereof within five (5) business days. 
 3.10 Licenses to Intrexon. Subject to the terms and conditions of this
Agreement, Soligenix hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by Soligenix or its Affiliates, solely to the extent necessary for
Intrexon to conduct those responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any Intrexon subcontractors as permitted in accord with Section 4.6 or as otherwise
permitted to be used by Intrexon in conjunction with support services under Section 4.7 (subject to JSC research plan approval). 
 3.11 Restrictions Relating to Intrexon Materials. Soligenix and its permitted sublicensees shall use the Intrexon Materials solely for purposes of the Melioidosis Program and not for any other
purpose without the prior written consent of Intrexon. With respect to the Intrexon Materials comprising Intrexon’s vector assembly technology, Soligenix shall not, and shall ensure that Soligenix personnel and permitted sublicensees do not,
except as otherwise permitted in this Agreement (a) distribute, sell, lend or otherwise transfer such Intrexon Materials to any Third Party; (b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials
without Intrexon’s written consent; or (c) analyze such Intrexon Materials or in any way attempt to reverse engineer or sequence such Intrexon Materials. 

  
 17 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 4 
 OTHER RIGHTS AND OBLIGATIONS 
 4.1 Development and Commercialization. Subject to Sections 4.6 and 4.7, Soligenix shall be solely responsible for the development and Commercialization of Soligenix Products. Soligenix shall be
responsible for all costs incurred in connection with the Melioidosis Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s
manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Soligenix Product, to
the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with
respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Soligenix Product (which
research costs shall be reimbursed by Soligenix); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within clause (a) of the previous sentence shall include without limitation
the scale-up of Intrexon Materials for generating data for manufacturing-related regulatory approval submissions and Commercialization of Soligenix Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it
elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Soligenix (with Intrexon’s consent). 
 4.2 Transfer of Technology and Information. The JSC shall develop a plan and protocol for each project and timing for the transfer of relevant data and materials between the Parties. 

4.3 Information and Reporting. Soligenix will keep Intrexon informed about Soligenix’s efforts to develop and Commercialize
Soligenix Products, including reasonable and accurate summaries of Soligenix’s (and its Affiliates’ and, if applicable, (sub)licensees’) development plans (as updated), including regulatory plans, marketing plans (as updated),
progress towards meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Soligenix Products, including initiation or completion of a
Regulatory Trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, Soligenix Product adverse safety events, receipt of Regulatory Approval, or
commercial launch. As set forth in Section 3.7 above, Soligenix shall also provide to Intrexon copies of all final Regulatory Trial protocols and reports, and regulatory correspondence and filings generated by Soligenix as soon as practical
after they become available. Intrexon will keep Soligenix informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Soligenix Products (and Intrexon Materials relevant thereto) and otherwise perform
its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon 

  
 18 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Soligenix and Intrexon will be
coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Soligenix Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

 4.4 Regulatory Matters. At all times after the Effective Date, Soligenix shall own and maintain, at its own cost, all
regulatory filings and regulatory approvals for Soligenix Products that Soligenix is developing or Commercializing pursuant to this Agreement. As such, Soligenix shall be responsible for reporting all adverse events related to such Soligenix
Products to the appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. To the extent that Intrexon will itself develop, or in collaboration with other third parties
develop, Intrexon Materials outside of the Field, either Party may request that Soligenix and Intrexon establish and execute a separate safety data exchange agreement, which agreement will address and govern the timely exchange of safety information
generated by Soligenix, Intrexon, and relevant third parties with respect to specific Intrexon Materials. 
 4.5
Diligence. 
 (a) Soligenix shall use, and shall require its sublicensees to use, Diligent Efforts to develop and
Commercialize Soligenix Products. Activities and success of Soligenix relating to ongoing active pursuit of Government Funding to develop or Commercialize Soligenix Products shall be considered in determining whether Soligenix is using Diligent
Efforts in accord with this Section 4.5(a). 
 (b) Without limiting the generality of the foregoing, Intrexon may,
from time to time, notify Soligenix that it believes it has identified a Superior Therapy, and in such case Intrexon shall provide to Soligenix its then-available information about such therapy and reasonable written support for its conclusion that
the therapy constitutes a Superior Therapy. Soligenix shall have the following obligations with respect to such proposed Superior Therapy: (i) within ninety (90) days after such notification, Soligenix shall prepare and deliver to the JSC
for review and approval a development plan detailing how Soligenix will pursue the Superior Therapy (including a proposed budget) along with a comparative analysis outlining the economic impact to both Intrexon and Soligenix to developing the
Superior Therapy compared to the existing product; (ii) assuming the JSC approves development of the Superior Therapy, Soligenix shall revise the development plan as directed by the JSC; and (iii) following approval of the development plan
by the JSC, Soligenix shall use Diligent Efforts to pursue the development of the Superior Therapy under the Melioidosis Program in accordance with such development plan. If Soligenix fails to comply with the foregoing obligations, or if Soligenix
unreasonably exercises its casting vote at the JSC to either (x) prevent the approval of a development plan for a Superior Therapy; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC;
or (z) approve a development plan that is insufficient in view of the nature and magnitude of the opportunity presented by the Superior 

  
 19 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Therapy, then Intrexon shall have the termination right set forth in Section 10.2(c) (subject to the limitation set forth therein). For clarity, any dispute arising under this 4.5, including
any dispute as to whether a proposed project constitutes a Superior Therapy (as with any other dispute under this Agreement) shall be subject to dispute resolution in accordance with Article 11. 

(c) The activities of Soligenix’s Affiliates and any sublicensees of Soligenix permitted in accord with Section 3.2
shall be attributed to Soligenix for the purposes of evaluating Soligenix’s fulfillment of the obligations set forth in this Section 4.5. 
 4.6 Manufacturing. Intrexon shall have the option and, in the event it so elects, shall use Diligent Efforts, to perform any manufacturing activities in connection with the Melioidosis Program of
the Intrexon Materials, including through the use of a suitable Third Party contract manufacturer. To the extent that Intrexon so elects, either Party may request that Soligenix and Intrexon establish and execute a separate manufacturing and supply
agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon
pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon
does not manufacture Intrexon Materials or bulk quantities of other components of Soligenix Products, then Intrexon shall provide to Soligenix or a contract manufacturer selected by Soligenix and approved by Intrexon all Information Controlled by
Intrexon that is (a) related to the manufacturing of such Intrexon Materials or bulk quantities of other components of Soligenix Products for use in the Field and (b) reasonably necessary to enable Soligenix or such contract manufacturer
(as appropriate) for the sole purpose of manufacturing such Intrexon Materials or bulk quantities of other components of Soligenix Products. The costs and expenses incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any
manufacturing Information transferred hereunder to Soligenix or its contract manufacturer shall not be further transferred to any Third Party, including any sublicensee of Soligenix, or any Soligenix Affiliate without the prior written consent of
Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit Soligenix to switch manufacturers. 
 4.7 Support Services. The JSC will meet promptly following the Effective Date and establish a plan under which Intrexon will provide support services to Soligenix for the research and development
of Soligenix Products under the Melioidosis Program, which initial plan may be amended from time to time by the JSC. Wherever commercially reasonable, such plan shall take into account and prioritize pursuit of Government Funding to support
development activities and a strategy to secure funding. In conjunction with Government Funding and/or in addition as is reasonable for development of the Melioidosis Program, Soligenix will compensate Intrexon for such support services with cash
payments equal to Intrexon’s Fully Loaded Cost in connection with such services. Additionally, from time to time, on an ongoing basis, Soligenix shall request, or Intrexon may propose, that Intrexon perform certain additional support services
with respect to researching and developing new Soligenix 

  
 20 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Products or improving the manufacturing or processing methods for any existing Soligenix Products. To the extent that the Parties mutually agree that Intrexon should perform such additional
services, the Parties shall negotiate in good faith the terms under which services would be performed, it being understood that Intrexon would be compensated for such services by cash payments equal to Intrexon’s Fully Loaded Cost in connection
with such services. 
 4.8 Compliance with Law. Each Party shall comply, and shall ensure that its Affiliates,
(sub)licensees and Third Party contractors comply, with all applicable laws, regulations, and guidelines applicable to the Melioidosis Program, including without limitation those relating to the transport, storage, and handling of Intrexon Materials
and Soligenix Products. 
 4.9 Trademarks and Patent Marking. To the extent permitted by applicable law and regulations,
Soligenix shall ensure that the packaging, promotional materials, and labeling for Soligenix Products, as appropriate, shall carry, in a conspicuous location, the applicable Intrexon Trademark(s), subject to Soligenix’s reasonable approval of
the size, position, and location thereof. Consistent with the U.S. patent laws, Soligenix shall ensure that Soligenix Products, or their respective packaging or accompanying literature as appropriate, bear applicable and appropriate patent markings
for Intrexon Patent numbers. Soligenix shall provide Intrexon with copies of any materials containing the Intrexon Trademarks or patent markings prior to using or disseminating such materials, in order to obtain Intrexon’s approval thereof.
Soligenix’s use of the Intrexon Trademarks and patent markings shall be subject to prior review and approval of the IPC. Soligenix acknowledges Intrexon’s sole ownership of the Intrexon Trademarks and agrees not to take any action
inconsistent with such ownership. Soligenix covenants that it shall not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any Soligenix Product). From time to time during the Term, Intrexon
shall have the right to obtain from Soligenix samples of Soligenix Product sold by Soligenix or its Affiliates or sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings, for the purpose of inspecting the
quality of such Soligenix Products, the use of the Intrexon Trademarks, or the accuracy of the patent markings. In the event that Intrexon inspects under this Section 4.9, Intrexon shall notify the result of such inspection to Soligenix in
writing thereafter. Soligenix shall comply with reasonable policies provided by Intrexon from time-to-time to maintain the goodwill and value of the Intrexon Trademarks. 
 4.10 Reporting Compliance. During the Term, in the event that Intrexon notifies Soligenix that Intrexon has reasonably concluded, after consultation with its outside advisors, that Intrexon will
have to consolidate Soligenix’s financial statements with its own, for so long as Intrexon reasonably believes that such consolidation is necessary, Soligenix shall used best efforts to comply with the following additional obligations:

 (a) Soligenix shall maintain at its principal place of business or, upon notice to Intrexon, at such other place as
Soligenix shall determine: 
 (i) a copy of Soligenix’s certificate of incorporation or organizational document and all
amendments thereto, together with executed copies of any powers of attorney pursuant to which any amendment has been executed; 

  
 21 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (ii) a copy of this Agreement; 

(iii) a copy of Soligenix’s federal, state, and local income tax returns and reports, if any; and 

(iv) minutes of meetings of Soligenix’s board of directors and shareholders or actions by written consent in lieu thereof, redacted
as necessary by Soligenix to exclude any sensitive or confidential information that Intrexon, by operation of law or contractual stipulation, is not permitted to receive. 
 (b) Soligenix shall keep its books and records consistent with US GAAP. 

(c) Intrexon at its own expense and upon reasonable notice, may examine any information it may reasonably request (including, to
the extent Soligenix has the right to provide such, the work papers of Soligenix’s internal and independent auditors) and make copies of and abstracts from the financial and operating records and books of account of Soligenix, and discuss the
affairs, finances and accounts of Soligenix with Soligenix and independent auditors of Soligenix, all at such reasonable times and as often as Intrexon or any agents or representatives of Intrexon may reasonably request. The rights granted pursuant
to this Section 4.10(c) are expressly subject to compliance by Intrexon with the safety, security and confidentiality procedures and guidelines of Soligenix, as such procedures and guidelines may be established from time to time. 

(d) As soon as available but no later than ninety (90) days after the end of each fiscal year, Soligenix shall cause to be
prepared and Intrexon to be furnished with an audited balance sheet as of the last day of such fiscal year and an audited income statement, a statement of stockholders’ equity and statement of cash flows for Soligenix for such fiscal year and
notes associated with each, in each case prepared in accordance with US GAAP, together with a report of Soligenix’s independent auditor that such statements have been prepared in accordance with US GAAP and present fairly, in all
material respects, the financial position, results of operations and cash flows of Soligenix. 
 (e) As soon as available
but no later than forty five (45) days after the end of each calendar quarter, Soligenix shall furnish the following to Intrexon an unaudited balance sheet as of the last day of such period, and an unaudited income statement, a statement of
cash flows and a statement of stockholders’ equity for Soligenix for such period, in each case prepared in accordance with US GAAP. 

  
 22 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (f) As requested by Intrexon on no more than a quarterly basis, a certificate,
executed by the Executive Officer of Soligenix, certifying on behalf of Soligenix the following: 
 (i) Soligenix maintains
accurate books and records reflecting its assets and liabilities and maintains proper and adequate internal accounting controls that provide assurance that (1) transactions are executed with management’s authorization;
(2) transactions are recorded as necessary to permit preparation of the consolidated financial statements of Soligenix and to maintain accountability for Soligenix’s consolidated assets; (3) access to the assets of Soligenix is
permitted only in accordance with management’s authorization; (4) the reporting of assets of Soligenix is compared with existing assets at regular intervals; and (5) accounts, notes and other receivables and inventory are recorded
accurately, and proper and adequate procedures are implemented to effect the collection of accounts, notes and other receivables on a current and timely basis. 
 (ii) under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; any such controls and procedures are effective to ensure that all material information
concerning (ii) Soligenix is made known on a timely basis to those individuals responsible for the preparation of any filings that may be required to be made by Intrexon with the SEC and other public disclosure documents. 

(g) Soligenix shall promptly prepare and furnish to Intrexon any information, whether written or oral, requested by Intrexon that
is reasonably necessary for purposes of Intrexon’s ongoing compliance with applicable law. 
 4.11 Modification of
Deadlines. The parties agree that the delivery deadlines in Section 4.10 will be modified to the extent necessary to ensure that such deliverables are provided by Soligenix no less than thirty (30) days prior (inclusive of any cure
period set forth in Section 10.2(a)) to the date necessary for Intrexon to meet any disclosure obligation under rules or regulations to which Intrexon may be or become subject from time to time. Intrexon will provide Soligenix with notice as
promptly as practicable regarding any changes in Intrexon’s disclosure obligations that would require a change in delivery deadlines or cure periods under this Section 4.11. 

4.12 Grant Activities. While the Parties anticipate that the Melioidosis Program will be supported predominantly by Government
Funding, Soligenix will not apply for or obtain grants, whether government or private, to fund activities under the Melioidosis Program, or use funds from any such grant to support activities under the Melioidosis Progam, without obtaining approval
in accord with this Section 4.12. The provisions and obligations of any prospective grant shall be presented in full by Soligenix to the JSC and IPC before any grant application submission and before any grant acceptance by Soligenix as soon as
is reasonably practical for the purpose of allowing the JSC and IPC to review the terms and scope of grant, to determine, within each such Committee’s respective authority, whether such grant (or related funds) would comply with the relevant
terms and obligations of this Agreement, and to approve or reject such application for or acceptance of such grant (or use of such grant funds). Intrexon shall not unreasonably use its casting vote at the IPC to withhold its approval of relevant
Government Funding grants or contracts to the extent that such grants or contracts do not (i) unreasonably restrict Intrexon’s rights to own or use any Inventions developed in the course of the Melioidosis Program consistent with Article 6
of this Agreement, or (ii) impose unreasonable restrictions upon Intrexon’s business or platform technology programs. 

  
 23 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 5 
 COMPENSATION 
 5.1 Technology Access Fee. In partial
consideration for Soligenix’s appointment as an exclusive channel collaborator in the Field and the other rights granted to Soligenix hereunder, Soligenix shall issue to Intrexon, as an access fee for commercial license rights to the Intrexon
IP granted under Section 3.1, certain equity interests in Soligenix (the “Technology Access Fee”) in accordance with the terms and conditions of the Stock Issuance Agreement of even date herewith (the “Equity
Agreement”). As set forth in the Equity Agreement, the Technology Access Fee will be either (i) one and one-half million dollars ($1,500,000) in cash, or (ii) that number of shares of Soligenix common stock having a value equaling
one and one-half million dollars ($1,500,000) (the number of shares to be calculated according to, or stipulated by, the terms of the Equity Agreement). Full payment of the Technology Access Fee, will occur within the timeframes set forth in the
Equity Agreement. Provided that all closing conditions for the Technology Access Fee Shares (as defined in the Equity Agreement) that are within the reasonable control of Intrexon have been satisfied or waived, the payment of the Technology Access
fee to Intrexon, including issuance of any Technology Access Fee Shares (as set forth in the Equity Agreement) to Intrexon, is a condition subsequent to the effectiveness of this Agreement.  

5.2 Milestones. Upon the attainment of certain milestone events by a Soligenix Product (whether such attainment is achieved by
Soligenix, an Affiliate of Soligenix, or sublicensee of Soligenix), Soligenix has agreed to make certain milestone payments to Intrexon as generally set forth below in Sections 5.2(a) and 5.2(b), which payments (subject to the terms and conditions
of the Equity Agreement) shall be either in cash or in an equivalent value of Soligenix common stock at Soligenix’s sole discretion. 
 (a) IND Milestone. Within thirty (30) days of the achievement of an IND Milestone Event (as defined in the Equity Agreement), Soligenix will pay to Intrexon, according to the timelines and
procedures set forth in the Equity Agreement, one of the following: (i) [*****] in cash, or (ii) the IND Milestone Shares (as defined in the Equity Agreement). 
 (b) Regulatory Approval Milestone. Within thirty (30) days of the achievement of an Approval Milestone Event (as defined in the Equity Agreement), Soligenix will pay to Intrexon, according to
the timelines and procedures set forth in the Equity Agreement, one of the following: (i) [*****] in cash, or (ii) the Approval Milestone Shares (as defined in the Equity Agreement). 

(c) If (A) a milestone event occurs that gives rise to a right for Intrexon to receive a milestone payment from Soligenix
under this Section 5.2, (B) that milestone event is 

  
 24 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
achieved by a Soligenix Product licensed to a Product Sublicensee under a respective Product Sublicense, and (C) Soligenix is due to receive a milestone payment from the Product Sublicensee
for achievement of that same (or substantially similar) milestone event by the sublicensed Soligenix Product under the respective Product Sublicense, then Intrexon may elect at its own discretion to waive that particular milestone payment from
Soligenix for that particular milestone event and instead designate the amount of the payment due to Soligenix from the Product Sublicensee for that same (or substantially similar) milestone event as Sublicensing Revenue for which Intrexon will be
entitled to receive revenue sharing under Section 5.4(b). If it so elects under this Section 5.2(c), Intrexon must notify Soligenix in writing of its waiver of the milestone and election to share the milestone payment due from the Product
Sublicensee as Sublicensing Revenue at least five (5) business days prior to the deadline for Soligenix to issue shares or otherwise make a payment for the waived milestone payment. The actual receipt by Intrexon of its full share of such a
Product Sublicensee milestone payment as Sublicensing Revenue will be a condition subsequent to making final any waiver of Intrexon’s rights to receive the particular milestone payment otherwise due from Soligenix under this Section 5.2.
Soligenix will pay Intrexon any amount due under this Section 5.2 within the later of (i) thirty (30) days from underlying milestone event, or (ii) ten (10) days following the date stipulated in the underlying Product
Sublicense for Soligenix to receive the milestone payment. 
 5.3 Equity Agreement Controls. All issuances of equity
interests to Intrexon shall be in accordance with the terms and conditions of the Equity Agreement, which Equity Agreement shall control to the extent they may conflict with Sections 5.1 or 5.2 of this Agreement. 

5.4 Revenue Sharing. 
 (a) No later than thirty (30) days after each calendar quarter in which there are positive Net Sales arising from the sale of any Soligenix Product in the Field in the Territory, Soligenix
shall pay to Intrexon on a Soligenix Product-by-Soligenix Product basis (i) a six percent (6%) royalty on the first one hundred million dollars ($100M) of annual Net Sales (cumulative worldwide for all Soligenix Products), (ii) an
eight percent (8%) royalty on the portion of annual Net Sales exceeding one hundred million dollars ($100M) up to and including two hundred million dollars ($200M) of annual Net Sales (cumulative worldwide for all Soligenix Products),
(iii) a ten percent (10%) royalty on the portion of annual Net Sales exceeding two hundred million dollars ($200M) up to and including three hundred million dollars ($300M) of annual Net Sales (cumulative worldwide for all Soligenix
Products), and (iv) a twelve percent (12%) royalty on the portion of annual Net Sales exceeding three hundred million dollars ($300M) (cumulative worldwide for all Soligenix Products). Commencing with the Effective Date, in the event there
are negative Net Sales for a particular Soligenix Product in any calendar quarter, neither Soligenix nor Intrexon shall owe any payments hereunder with respect to such Soligenix Product. To the extent that a portion of Net Sales for any calendar
quarter is derived from the sale of Soligenix Products by a Product Sublicensee, the royalty payment due to Intrexon for that portion of Net Sales derived from the Product Sublicensee shall in no event be greater than fifty percent (50%) of the
royalty payment due to Soligenix from the Product Sublicensee under the relevant Product Sublicense. 

  
 25 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (b) No later than thirty (30) days after each calendar quarter in which
Soligenix or any Soligenix Affiliate receives Sublicensing Revenue, Soligenix shall pay to Intrexon fifty percent (50%) of such Sublicensing Revenue. 
 5.5 Method of Payment. Cash payments due to Intrexon under this Agreement shall be paid in United States dollars by wire transfer to a bank in the United States designated in writing by Intrexon.
All references to “dollars” or “$” herein shall refer to United States dollars. 
 5.6 Payment Reports
and Records Retention. Within thirty (30) days after the end of each calendar quarter during which Net Sales have been generated, during which Sublicensing Revenue has been received, or during which a negative Net Sales has occurred,
Soligenix shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar quarter: 

(a) gross sales of each Soligenix Product on a country-by-country basis; 

(b) itemized calculation of Net Sales on a Soligenix Product-by-Soligenix Product and country-by-country basis (showing conversion
to dollars for any Net Sales derived in a currency other than dollars), showing all applicable deductions; 
 (c) the
amount of any negative Net Sales for the applicable calendar quarter; 
 (d) the amount of the payment (if any) due to
Intrexon pursuant to Section 5.4(a) and 5.4(b); 
 (e) the amount of taxes, if any, withheld from each of the
payments set forth in Sections 5.8(d) and 5.8(e) to comply with any applicable law; and 
 (f) the exchange rates used in
any of the foregoing calculations. 
 For three (3) years after each sale or other commercial use of Soligenix Product, or after incurring
any component item Soligenix incorporated into its calculation of Net Sales or otherwise impacting Soligenix’s calculations with regard to payments made to Intrexon in accord with Sections 5.4(a) or 5.4(b), Soligenix shall keep (and shall
ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate records of such sales and other relevant information in sufficient detail to confirm the accuracy of the payment calculations hereunder. 

5.7 Audits. 
 (a) Upon the written request of a Party, the other Party shall permit an independent certified public accounting firm of internationally recognized standing selected by

  
 26 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
the requesting Party, and reasonably acceptable to the other Party, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice,
the applicable records of the other Party and its Affiliates to verify, as applicable, the accuracy and timeliness of the reports and payments made by Soligenix under this Agreement or the amounts charged by Intrexon to Soligenix under this
Agreement as its Fully Loaded Cost. Such review may cover the records for sales made in any calendar year with respect to an audit of Soligenix, and for Fully Loaded Costs with respect to an audit of Intrexon, in each case ending not more than three
(3) years prior to the date of such request. The accounting firm shall disclose to both Parties whether the royalty reports or Fully Loaded Costs charges, as applicable, conform to the provisions of this Agreement and/or US GAAP, as
applicable, and the specific details concerning any discrepancies. Such audit may not be conducted more than once in any calendar year. 
 (b) If such accounting firm concludes that additional amounts were owed to Intrexon or over-charged by Intrexon during such period, as appliacble, Soligenix or Intrexon, respectively, shall pay
additional amounts, with interest from the date originally due with respect to royalty payments by Soligenix as set forth in Section 5.9, within thirty (30) days of receipt of the accounting firm’s written report. If the amount of the
underpayment or over-charging, as applicable, is greater than five percent (5%) of the total amount actually owed or charged for the period audited, then the other Party shall in addition reimburse the auditing Party for all costs related to
such audit; otherwise, the auditing Party shall pay all costs of the audit. In the event of overpayment of royalties by Soligenix, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding
calendar quarter(s); provided, however, that if such overpayment is reasonably expected to exceed the amount projected to be payable to Intrexon by Soligenix over next three (3) quarters, Intrexon will promptly repay to Soligenix any amount
exceeding that projected amount. 
 (c) The auditing Party shall (i) treat all information that it receives under
this Section 5.7 in accordance with the confidentiality provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with the other Party obligating such firm to retain all such financial
information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for Intrexon to enforce its rights under this Agreement. 
 5.8 Taxes. The Parties will cooperate in good faith to obtain the benefit of any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any amounts payable
hereunder. Soligenix shall deduct or withhold from any payments any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate
of, or the elimination of, applicable withholding tax, it may deliver to Soligenix or the appropriate governmental authority (with the assistance of Soligenix to the extent that this is reasonably required and is expressly requested in writing) the
prescribed forms necessary to reduce the applicable rate of withholding or to relieve Soligenix of its obligation to withhold tax, and Soligenix shall apply the reduced rate of withholding tax, or dispense with withholding tax, as

  
 27 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
the case may be, provided that Soligenix has received evidence of Intrexon’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at
least fifteen (15) days prior to the time that the payment is due. If, in accordance with the foregoing, Soligenix withholds any amount, it shall make timely payment to the proper taxing authority of the withheld amount, and send to Intrexon
proof of such payment within forty-five (45) days following that latter payment. 
 5.9 Late Payments. Any amount
owed by Soligenix to Intrexon under this Agreement that is not paid within the applicable time period set forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b) the highest rate permitted
under applicable law. 
 ARTICLE 6 
 INTELLECTUAL PROPERTY 
 6.1 Ownership.

 (a) Subject to the license granted under Section 3.1, all rights in the Intrexon IP shall remain with Intrexon.

 (b) Soligenix and/or Intrexon may solely or jointly conceive, reduce to practice or develop discoveries, inventions,
processes, techniques, and other technology, whether or not patentable, in the course of performing the Melioidosis Program (collectively “Inventions”). Each Party shall promptly provide the other Party with a detailed written
description of any such Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws. 
 (c) Intrexon shall solely own all right, title and interest in all Inventions made with, using, or otherwise incorporating Intrexon Channel Technology, together with all Patent rights and other
intellectual property rights therein (the “Channel-Related Program IP”). Soligenix hereby assigns all of its right, title and interest in and to the Channel-Related Program IP to Intrexon. Soligenix agrees to execute such documents
and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and the assignment thereof. 
 (d) Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other technology, whether or not patentable, that is conceived, reduced to practice
or developed by Soligenix solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of this Agreement, together with all patent rights and other intellectual
property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related Program IP. 

  
 28 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (e) All Information regarding Channel-Related Program IP shall be Confidential
Information of Intrexon. Soligenix shall be under appropriate written agreements with each of its employees, contractors, or agents working on the Melioidosis Program, pursuant to which such person shall grant all rights in the Inventions to
Soligenix (so that Soligenix may convey certain of such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Melioidosis Program. 

(f) All rights, technology, and intellectual property (A) owned by Soligenix or licensed from a Third Party by Soligenix as
of the Effective Date, or (B) thereafter developed by Soligenix independent of the Melioidosis Program, Intrexon Channel Technology, Intrexon IP or Intrexon Materials, shall be owned by and remain the property of Soligenix (the
“Soligenix Independent IP”). 
 6.2 Patent Prosecution. 

(a) Intrexon shall have the sole right, but not the obligation, at Intrexon’s expense, to (i) conduct and control the
filing, prosecution and maintenance of the Intrexon Patents, and (ii) conduct and control the filing, prosecution, and maintenance of any applications for patent term extension and/or supplementary protection certificates for the Intrexon
Patents that may be available as a result of the regulatory approval of any Soligenix Product. At the reasonable request of Intrexon, Soligenix shall cooperate with Intrexon in connection with such filing, prosecution, and maintenance, at
Intrexon’s expense. Except as otherwise set forth in this Section 6.2(a), under no circumstances shall Soligenix (A) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the
United States or elsewhere, that claims or uses or purports to claim or use or relies for support upon an Invention owned by Intrexon, (B) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon
Materials, or any Confidential Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology,
or (C) without prior approval of the IPC, file, attempt to file, or assist anyone else in filing, or attempting to file, any application for patent term extension or supplementary protection certificate for the Intrexon Patents, either in the
United States or elsewhere, that relies upon the regulatory approval of a Soligenix Product. 
 (b) Soligenix shall have
the sole right, but not the obligation, to conduct and control the filing, prosecution and maintenance of any Patents claiming Inventions that are owned by Soligenix or its Affiliates and not assigned to Intrexon under Section 6.1(c)
(“Soligenix Program Patents”). At the reasonable request of Soligenix, Intrexon shall cooperate with Soligenix in connection with such filing, prosecution, and maintenance, at Soligenix’s expense. Under no circumstances shall
Intrexon (A) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United States or elsewhere, that claims or uses or purports to claim or use or relies for support upon an
Invention owned by Soligenix, (B) use, attempt to use, or assist anyone else in using or attempting to use, the Soligenix Independent IP, any Inventions that are owned by Soligenix or its Affiliates and

  
 29 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
not assigned to Intrexon under Section 6.1(c) or any Confidential Information of Soligenix to support the filing of a Patent application, either in the United States or elsewhere, that
contains claims directed to the Soligenix Independent IP or Inventions that are owned by Soligenix or its Affiliates and not assigned to Intrexon under Section 6.1(c). 
 (c) As used in this Section, “Prosecuting Party” means Intrexon in the case of Intrexon Patents and Soligenix in the case of Soligenix Program Patents. The Prosecuting Party shall
be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and Soligenix Program Patents,
as applicable. The Prosecuting Party shall: 
 (i) regularly provide the other Party in advance with reasonable information
relating to the Prosecuting Party’s prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings
and correspondence that the Prosecuting Party proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public, the Prosecuting Party may, in lieu of directly
providing copies of such information to such other Party, provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 

(ii) consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; provided,
however, that if, within fifteen (15) days after providing any documents to the non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may
have comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon; 
 (iii) consult with the non-Prosecuting Party before taking any action that would reasonably be expected to have a material adverse impact on the scope of claims within the Intrexon Patents and Soligenix
Program Patents, as applicable. 

  
 30 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 6.3 Infringement of Patents by Third Parties. 

(a) Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take appropriate
action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or lawsuit or other
appropriate action. 
 (b) Notwithstanding the foregoing, Soligenix shall have the first right, but not the obligation,
to take appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field Infringement”), either by
settlement or lawsuit or other appropriate action. If Soligenix exercises the foregoing right, Intrexon agrees to be named in any such action if required. If Soligenix fails to take the appropriate steps to enforce Product-Specific Program Patents
against any Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the
obligation), at its own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action. 
 (c) With respect to any Field Infringement that cannot reasonably be abated through the enforcement of Product-Specific Program Patents pursuant to Section 6.3(b) but can reasonably be abated
through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following courses of action: (i) enforce one or more of the applicable Intrexon Patent(s) in a
commercially reasonable manner against such Field Infringement, or (ii) [*****]. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good
faith with Soligenix on such determination. For the avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement. 

(d) In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate with the
enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party’s expense (except with respect to an action under Section 6.3(c), where all costs and expenses
will be shared equally in accordance with terms thereof). 
 (e) Soligenix shall not settle or otherwise compromise any
action under this Section 6.3 in a way that diminishes the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be unreasonably
withheld. Intrexon shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of Soligenix in the Field or adversely affects any Intrexon Patent with respect to the Field without
Soligenix’s prior written consent, which consent shall not be unreasonably withheld. 

  
 31 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (f) Except as otherwise agreed to by the Parties in writing, any settlements,
damages or other monetary awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party controlling such action, and second, to the costs and expenses
(if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action initiated by Intrexon pursuant to Section 6.3(a) that does
not involve Field Infringement, or in any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any action initiated by Soligenix pursuant to Section 6.3(b),
Soligenix shall retain one hundred percent (100%) of any Recovery, but such Recovery shall be shared with Intrexon as “Net Sales” under Section 5.4(a). In any action initiated by Intrexon or Soligenix pursuant to
Section 6.3(c), the Parties shall share the Recovery equally, the Parties shall bear the costs and expenses of such enforcement equally, and such Recovery shall not be deemed to constitute “Net Sales” per the preceding sentence.

 (g) Soligenix shall promptly notify Intrexon in writing of any suspected, alleged, threatened, or actual Infringement
of which it becomes aware, and Intrexon shall promptly notify Soligenix in writing of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware. 

ARTICLE 7 

CONFIDENTIALITY 
 7.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and shall not
publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this Agreement, except to the extent that the receiving Party
can demonstrate by competent evidence that specific Confidential Information: 
 (a) was already known to the receiving
Party and can be demonstrated by written records, other than under an obligation of confidentiality, at the time of disclosure by the other Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 

(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through
any act or omission of the receiving Party in breach of this Agreement; 
 (d) was disclosed to the receiving Party,
other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or 

  
 32 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (e) was independently discovered or developed by the receiving Party without the
use of Confidential Information belonging to the disclosing Party, as documented by the receiving Party’s written records. 

The foregoing non-use and non-disclosure obligation shall continue (i) indefinitely, for all Confidential Information that qualifies
as a trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases. 
 7.2 Authorized Disclosure. Notwithstanding the limitations in this Article 7, either Party may disclose the Confidential Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances: 
 (a) complying with applicable laws or regulations or valid court
orders, provided that the Party making such disclosure provides the other Party with reasonable prior written notice of such requirement, request or demand for disclosure and makes a reasonable effort to obtain, or to assist the other Party
in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation required, or for which the order was issued;

 (b) to regulatory authorities in order to seek or obtain approval to conduct Regulatory Trials, or to gain regulatory
approval, of Soligenix Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators, provided that the Party making such disclosure (i) provides the other Party with reasonable opportunity
to review any such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential Information and (ii) does not unreasonably reject any such suggestions; 

(c) disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the confidentiality of
such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 
 (d) disclosure on a need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs or clinical investigators) who agree to be bound by obligations of
confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; and 
 (e) disclosure of
the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7. 

7.3 Publicity; Publications. The Parties agree that the public announcement of the execution of this Agreement and the Equity
Agreement shall be substantially in the form of a press release and/or the filing of a Form 8-K by Soligenix, which shall be mutually agreed to by the Parties. Each Party will provide the other Party with the opportunity to review and comment,

  
 33 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
prior to submission or presentation, on external reports, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral
presentations) that refer to the Melioidosis Program or programs that are approved by the JSC. For such reports, publications, and presentations, the disclosing Party will provide the other Party at least fifteen (15) calendar days for review
of the proposed submission or presentation. In the case of a Form 8-K filing, such shall be provided to Intrexon by Soligenix as soon as practicable prior to filing. For reports and manuscripts, the disclosing Party will provide the other Party at
least thirty (30) days for review of the report or manuscript. The presenting Party will act in good faith to incorporate the comments of the other Party and shall, in any event, redact any Confidential Information of the other Party and
cooperate with the other Party to postpone such submissions or presentations if necessary to provide the other Party with sufficient time to prepare and file any related Patent applications before the submission or presentation occurs, as
appropriate. 
 7.4 Terms of the Agreement. Each Party shall treat the terms of this Agreement as the Confidential
Information of other Party, subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the
Effective Date or at some point during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such
confidential treatment is reasonably available to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential
treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. The other
Party shall promptly provide any such comments. 
 7.5 Proprietary Information and Operational Audits. 

(a) For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence obligations of
Article 4, and the confidentiality obligations under Article 7, Soligenix acknowledges that Intrexon’s authorized representative(s), during regular business hours may (i) examine and inspect Soligenix’s facilities and
(ii) inspect all data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection hereunder shall require five (5) business days written notice from Intrexon to Soligenix.
Soligenix will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review. 
 (b) For the purpose of confirming compliance with the diligence obligations of Section 4.5, and the confidentiality obligations under Article 7, Intrexon acknowledges that Soligenix authorized
representative(s), during regular business hours may (i) examine and inspect Intrexon’s facilities and (ii) inspect all data and work products relating to this Agreement. Any examination or inspection hereunder shall require five
(5) business days written notice from Soligenix to Intrexon. Intrexon will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Soligenix for the aforementioned compliance review. 

  
 34 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) In view of the Intrexon Confidential Information, Intrexon Know-How, and
Intrexon Materials transferred to Soligenix hereunder, Intrexon from time-to-time, but no more than quarterly, may request that Soligenix confirm the status of the Intrexon Materials at Soligenix (i.e. how much used, how much shipped, to whom and
any unused amounts destroyed (by whom, when) as well as any amounts returned to Intrexon or destroyed). Within ten (10) business days of Soligenix’s receipt of any such written request, Soligenix shall provide the written report to
Intrexon. 
 7.6 Intrexon Commitment. Intrexon shall use reasonable efforts to obtain an agreement with its other
licensees and channel partners or collaborators to enable Soligenix to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain approval to conduct Regulatory
Trials, or to gain regulatory approval of, Soligenix Products, in a manner consistent with the provisions of Section 7.2(b). 
 ARTICLE 8 
 REPRESENTATIONS AND
WARRANTIES 
 8.1 Representations and Warranties of Soligenix. Soligenix hereby represents and
warrants to Intrexon that, as of the Effective Date: 
 (a) Corporate Power. Soligenix is duly organized and validly
existing under the laws of Delaware and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. Soligenix is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Soligenix’s
behalf has been duly authorized to do so by all requisite corporate action. 
 (c) Binding Agreement. This Agreement is a
legal and valid obligation binding upon Soligenix and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting
creditors’ rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Soligenix does not conflict with
any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound. Soligenix is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the
validity of this Agreement. 

  
 35 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 8.2 Representations and Warranties of Intrexon. Intrexon hereby represents and
warrants to Soligenix that, as of the Effective Date: 
 (a) Corporate Power. Intrexon is duly organized and validly
existing under the laws of Virginia and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. Intrexon is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Intrexon’s behalf
has been duly authorized to do so by all requisite corporate action. 
 (c) Binding Agreement. This Agreement is a legal
and valid obligation binding upon Intrexon and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting
creditors’ rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the
validity of this Agreement 
 (d) Third Party Licenses. Except as previously disclosed by Intrexon to Soligenix, as of
the Effective Date there are no material terms and conditions under any relevant sublicenses requiring disclosure to Soligenix under Section 3.9(e). 
 (e) Additional Intellectual Property Representations. 
 (i) Intrexon
possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to Soligenix with respect to the Intrexon Patents under this Agreement; 
 (ii) The Intrexon Patents existing as of the Effective Date constitute all of the Patents Controlled by Intrexon as of such date that are necessary for the development, manufacture and Commercialization
of Soligenix Products; 
 (iii) Intrexon has not granted, and during the Term Intrexon will not grant, any right or license, to
any Third Party under the Intrexon IP that conflicts with the rights or licenses granted or to be granted to Soligenix hereunder; 
 (iv) There is no pending litigation, and Intrexon has not received any written notice of any claims or litigation, seeking to invalidate or otherwise challenge the Intrexon Patents or Intrexon’s
rights therein; 

  
 36 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (v) None of the Intrexon Patents is subject to any pending re-examination, opposition,
interference or litigation proceedings; 
 (vi) All of the Intrexon Patents have been filed and prosecuted in accordance with
all applicable laws and have been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 
 (vii) Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of Intrexon’s
products and technology providing Intrexon, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other
of such persons, during the period of employment or contract by Intrexon (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to Soligenix herein), and Intrexon is not aware
that any of its employees or consultants is in material violation thereof; 
 (viii) To Intrexon’s knowledge, there is no
infringement, misappropriation or violation by third parties of any Intrexon Channel Technology or Intrexon IP in the Field; 

(ix) There is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others against Intrexon that
Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology or Intrexon IP, and Intrexon has not received any written notice
of such claim; 
 (x) To Intrexon’s knowledge, no employee of Intrexon is the subject of any claim or proceeding involving
a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer
(A) where the basis of such violation relates to such employee’s employment with Intrexon or actions undertaken by the employee while employed with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel
Technology in the Field; 
 (xi) None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to Intrexon’s
knowledge, the Intrexon Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or unenforceable by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending or, to
Intrexon’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intrexon Patents; and 
 (xii) Except as otherwise disclosed in writing to Soligenix, Intrexon: (A) is in material compliance with all statutes, rules or regulations applicable to the ownership,

  
 37 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under
development, manufactured or distributed by Intrexon in the Field (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the
United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses,
certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would, individually or in the aggregate, result in a material adverse
effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force and effect and Intrexon is not in material violation of any term of any
such Authorizations; and (D) since January 1, 2011, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local
or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or
foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or proceeding; (2) has not received notice that the FDA or any other federal, state, local or foreign
governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or
regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any
Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or
supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post
sale warning, letters to customers, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to Intrexon’s knowledge, no third party has initiated, conducted or
intends to initiate any such notice or action. 
 except, in each of (ix) through (xii), for any instances which would not, individually or
in the aggregate, result in a material adverse effect on the rights granted to Soligenix hereunder or Intrexon’s ability to perform its obligations hereunder. 
 8.3 Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8 OR IN THE EQUITY AGREEMENT, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR
IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

  
 38 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 9 
 INDEMNIFICATION 
 9.1 Indemnification by Intrexon.
Intrexon agrees to indemnify, hold harmless, and defend Soligenix and its Affiliates and their respective directors, officers, employees, and agents (collectively, the “Soligenix Indemnitees”) from and against any and all
liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’ fees) (collectively, “Losses”) resulting from any claims, suits, actions, demands, or other proceedings brought by a Third
Party (collectively, “Claims”) to the extent arising from (a) the negligence or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport
of Intrexon Materials by or on behalf of Intrexon or its Affiliates, licensees (other than Soligenix) or sublicensees; or (c) breach by Intrexon of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing,
Intrexon shall not have any obligation to indemnify the Soligenix Indemnitees to the extent that a Claim arises from (i) the negligence or willful misconduct of Soligenix or any of its Affiliates, licensees, or sublicensees, or their respective
employees or agents; or (ii) a breach by Soligenix of a representation, warranty, or covenant of this Agreement. 
 9.2
Indemnification by Soligenix. Soligenix agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates and Third Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to
Intrexon intellectual property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the relevant upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses
resulting from Claims, to the extent arising from any of the following: (a) the negligence or willful misconduct of Soligenix or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of
Intrexon Materials by or on behalf of Soligenix or its Affiliates, licensees, or sublicensees; (c) breach by Soligenix of any material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture,
regulatory approval, handling, storage, transport, distribution, sale or other disposition of any Soligenix Product by or on behalf of Soligenix or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, Soligenix shall not have
any obligation to indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the negligence or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by
Intrexon of a representation, warranty, or covenant of this Agreement. 
 9.3 Product Liability Claims. Notwithstanding
the provisions of Section 9.2, any Losses arising out of any Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development,
manufacture or Commercialization of any Soligenix Products for use or sale in the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s 

  
 39 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
product liability insurance (“Excess Product Liability Costs”), shall be paid by [*****], except to the extent such Losses arise out of any Third-Party Claim based on the gross
negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ sublicensees, or any of the respective officers, directors, employees and agents of each of the foregoing entities, in the performance of obligations or exercise of
rights under this Agreement. 
 9.4 Control of Defense. As a condition precedent to any indemnification obligations
hereunder, any entity entitled to indemnification under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim. If such Claim falls within the
scope of the indemnification obligations of this Article 9, then the indemnifying Party shall assume the defense of such Claim with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall cooperate with the indemnifying
Party in such defense. The indemnified Party may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable for any litigation costs or
expenses incurred by the indemnified Party without the indemnifying Party’s written consent, such consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim if such settlement (a) does not fully and
unconditionally release the indemnified Party from all liability relating thereto or (b) adversely impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified Party otherwise agrees in
writing. 
 9.5 Insurance. Immediately prior to, and during marketing of Soligenix Products, Soligenix shall maintain in
effect and good standing a product liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. Immediately prior to, and during the conduct of any clinical trials, Soligenix shall maintain in
effect and good standing a clinical trials liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. At Intrexon’s reasonable request, Soligenix shall provide Intrexon with all details
regarding such policies, including without limitation copies of the applicable liability insurance contracts. Soligenix shall use reasonable efforts to include Intrexon as an additional insured on any such policies. 

ARTICLE 10 

TERM; TERMINATION 
 10.1 Term. The term of this Agreement shall commence upon the Effective Date and shall continue until terminated pursuant to Section 10.2 or 10.3 (the “Term”). 

10.2 Termination for Material Breach; Termination Under Section 4.5(b) 

(a) Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the other Party
commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the 

  
 40 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
nonbreaching Party specifying such breach; provided, however, that if Soligenix commits any breach of the provisions of Section 4.10 of this Agreement, Intrexon shall have the right to
terminate this Agreement if Soligenix fails after notice from Intrexon to cure such breach within thirty (30) days following written notice thereof. 
 (b) Intrexon shall have the right to terminate this Agreement, at its sole discretion, if any necessary shareholder, member, exchange, and/or board of director approvals of Soligenix have not been
obtained, and the Technology Access Fee Shares (as defined in the Equity Agreement) have not been issued, within the time frames set forth in the Equity Agreement. 
 (c) Intrexon shall have the right to terminate this Agreement under the circumstances set forth in Section 4.5(b) upon written notice to Soligenix, such termination to become effective sixty
(60) days following such written notice unless Soligenix remedies the circumstances giving rise to such termination within such sixty (60) day period. 
 (d) Intrexon shall have the right to terminate this Agreement should Soligenix execute any purported assignment of this Agreement contrary to the prohibitions in Section 12.8, such termination
occurring upon Intrexon providing written notice to Soligenix and becoming effective immediately upon such written notice. 

(e) In recognition of the need for Soligenix to raise capital necessary to carry out its obligations under this Agreement,
notwithstanding the foregoing, during the twelve (12) month period commencing on the Effective Date, neither Party shall have the right to terminate this Agreement under Section 10.2(a) based on the failure of the other Party to use
Diligent Efforts or to comply with any other diligence obligations hereunder (including without limitation Section 4.5), nor shall Intrexon have the right to terminate this Agreement under Section 10.2(c). 

10.3 Termination by Soligenix. Soligenix shall have the right to voluntarily terminate this Agreement in its entirety upon ninety
(90) days written notice to Intrexon at any time. 
 10.4 Effect of Termination. In the event of termination of this
Agreement pursuant to Section 10.2 or Section 10.3, the following shall apply: 
 (a) Retained Products.
Soligenix shall be permitted to continue the development and Commercialization in the Field of any product resulting from the Melioidosis Program that, at the time of termination, satisfies at least one of the following criteria (a “Retained
Product”): 
 (i) the particular product is a Soligenix Product that is being sold or has been sold within the past
six (6) months by Soligenix (or, as may be permitted under this Agreement, its Affiliates and, if applicable, (sub)licensees) triggering revenue sharing payments therefor under Section 5.4(a) of this Agreement, 

  
 41 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (ii) the particular product is a Soligenix Product that has received regulatory
approval, 
 (iii) the particular product is a Soligenix Product that has received a government procurement contract under an
Emergency Use Authorization by the FDA or similar designation, 
 (iv) the particular product is a Soligenix Product that is
the subject of an application for regulatory approval in the Field that is pending before the applicable regulatory authority, 

(v) the particular product is a Soligenix Product that is the subject of an ongoing or completed Phase II clinical trial, or 

(vi) the particular product is a Soligenix Product that is the subject of a successful and completed animal efficacy study or an ongoing
animal efficacy study, which study (if successful) would be sufficient under relevant government laws or regulations and absent human efficacy trials to permit sale of the particular product under an Emergency Use Authorization or other relevant
statutory or regulatory exemptions that permit commercial sale absent a showing to the FDA of safety and effectiveness of the subject product through the conventional route of human clinical trials. 

Such right to continue development and Commercialization shall be subject to Soligenix’s full compliance with the payment provisions in Article 5, a
continuing obligation for Soligenix to use in accord with Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and Commercialize any Retained Products, and all other provisions of this Agreement that survive termination. 

(b) Termination of Licenses. Except as necessary for Soligenix to continue to obtain regulatory approval for, develop, use,
manufacture and Commercialize the Retained Products in the Field as permitted by Section 10.4(a), all rights and licenses granted by Intrexon to Soligenix under this Agreement shall terminate and shall revert to Intrexon without further action
by either Intrexon or Soligenix. Soligenix’s license with respect to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1. 

(c) Reverted Products. All Soligenix Products other than the Retained Products shall be referred to herein as the
“Reverted Products.” Soligenix shall immediately cease, and shall cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and Soligenix shall not
use or practice, nor shall it cause or permit any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. Soligenix shall immediately discontinue making
any representation regarding its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products. 

  
 42 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (d) Intrexon Materials. Soligenix shall promptly return, or at Intrexon’s
request, destroy, any Intrexon Materials in Soligenix’s possession or control at the time of termination other than any Intrexon Materials necessary for the continued development, regulatory approval, use, manufacture and Commercialization of
the Retained Products in the Field. 
 (e) Licenses to Intrexon. Soligenix is automatically deemed to grant to Intrexon a
worldwide, fully paid, royalty-free, exclusive (even as to Soligenix and its Affiliates), irrevocable, license (with full rights to sublicense) under the Soligenix Termination IP, to make, have made, import, use, offer for sale and sell Reverted
Products and to use the Intrexon Channel Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by Soligenix in Reverted Products pursuant to Section 10.4(c). The Parties shall also take
such actions and execute such other instruments and documents as may be reasonably necessary to document such license to Intrexon. 
 (f) Regulatory Filings. Soligenix shall promptly assign to Intrexon, and will provide full copies of, all regulatory approvals and regulatory filings that relate specifically and solely to Reverted
Products. Soligenix shall also take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and
regulatory filings that relate both to Reverted Products and other products, Soligenix shall provide copies of the portions of such regulatory filings that relate to Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining
the benefits of such regulatory approvals with respect to the Reverted Products. 
 (g) Data Disclosure. Soligenix shall
provide to Intrexon copies of the relevant portions of all material reports and data, including Regulatory Trial data and reports, obtained or generated by or on behalf of Soligenix or its Affiliates to the extent that they relate to Reverted
Products, within sixty (60) days of such termination unless otherwise agreed, and Intrexon shall have the right to use any such Information in developing and Commercializing Reverted Products and to license any Third Parties to do so.

 (h) Third Party Licenses. At Intrexon’s request, Soligenix shall promptly provide to Intrexon copies of all Third
Party agreements under which Soligenix or its Affiliates obtained a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture and/or Commercialization of the Reverted Products. At
Intrexon’s request such that Intrexon may Commercialize the Reverted Products, Soligenix shall promptly work with Intrexon to either, as appropriate (i) assign to Intrexon the Third Party agreement(s), or (ii) grant a sublicense (with
an appropriate scope) to Intrexon under the Third Party agreement(s). Thereafter Intrexon shall be fully responsible for all obligations due for its actions under the sublicensed or assigned Third Party agreements. Notwithstanding the above, if
Intrexon does not wish to assume any financial or other obligations associated with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so notify Soligenix and Soligenix shall not make such
assignment or grant such sublicense (or cause it to be made or granted). 

  
 43 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (i) Remaining Materials. At the request of Intrexon, Soligenix shall transfer to
Intrexon all quantities of Reverted Product (including final products or work-in-process) in the possession of Soligenix or its Affiliates. Soligenix shall transfer to Intrexon all such quantities of Reverted Products without charge, except that
Intrexon shall pay the reasonable costs of shipping. 
 (j) Third Party Vendors. At Intrexon’s request, Soligenix
shall promptly provide to Intrexon copies of all agreements between Soligenix or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or distribution of Reverted Products in the Territory. At
Intrexon’s request, Soligenix shall promptly: (i) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign (or cause to be assigned), such agreements to
Intrexon, and (ii) with respect to all other such Third Party agreements, Soligenix shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. Soligenix shall be liable for any costs associated with assigning a
Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such costs are directly related to Soligenix’s breach. For the avoidance of doubt, Intrexon shall have no obligation to assume
any of Soligenix’s obligations under any Third Party agreement. 
 (k) Commercialization. Intrexon shall have the
right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Soligenix, to take any such actions in connection with such activities as Intrexon (or its designee),
at its discretion, deems appropriate. 
 (l) Confidential Information. Each Party shall promptly return, or at the other
Party’s request destroy, any Confidential Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain (i) a single copy of each item
of Confidential Information of the other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that is maintained as archive copies
on the recipient Party’s disaster recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained Products (in the case of Soligenix) or
Reverted Products (in the case of Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information retained in accordance with this
Section 10.4(l). 
 10.5 Surviving Obligations. Termination or expiration of this Agreement shall not affect any
rights of either Party arising out of any event or occurrence prior to termination, including, without limitation, any obligation of Soligenix to pay any amount which became due and payable under the terms and conditions of this Agreement prior to
expiration or such 

  
 44 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
termination. The following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 (as applicable with respect to 10.4(b)), 3.6, 4.10, 4.11, 5.6 through
5.9, 6.1, 6.2 (with subsection (c) surviving only to the extent relating to Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or Commercialized at such time, if any), 6.3 (as
applicable with respect to Intrexon Patents relevant to Retained Products), 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9, 11, and 12; and any relevant definitions in Article 1. Further, Article 7 and Sections 4.5(a), 4.5(c), 4.12, 5.2 through 5.9,
and 9.5 will survive termination of this Agreement to the extent there are applicable Retained Products. 
 ARTICLE 11

 DISPUTE RESOLUTION 

11.1 Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under
this Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this
Agreement, including, without limitation, any alleged failure to perform, or breach, of this Agreement (other than with regard to any issue wholly within the authority of a Committee as granted by this Agreement being finally resolved via casting
vote at such Committee) , or any issue relating to the interpretation or application of this Agreement, then upon the request of either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which
good faith efforts shall include at least one in-person meeting between the Executive Officers of each Party. If the matter is not resolved within thirty (30) days following the written request for discussions, either Party may then invoke the
provisions of Section 11.2. 
 11.2 Arbitration. Any dispute, controversy, difference or claim which may arise
between the Parties, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance, application or
termination of this Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding “baseball arbitration” as follows. Either Party, following the end of the thirty (30) day
period referenced in Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party, with the arbitration to be held in the state where the other Party’s principal office is located (or
some other place as may be mutually agreed by the Parties). Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to agree on an arbitrator to resolve the issue, which arbitrator shall be neutral and
independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering agreements in the pharmaceutical and biotechnology industries, and shall have some experience in
mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request by a Party for arbitration, then each Party shall select an arbitrator meeting the foregoing
criteria and the two (2) arbitrators 

  
 45 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an arbitrator(s) is selected (in the
case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth its proposed terms for the resolution for the matter at issue
(the “Proposed Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide the arbitrator(s) a copy of this Agreement, as it may be amended at such time. Within
fifteen (15) days after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a response to the other Party’s Support Memorandum. Neither Party
may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section 11.2; provided that, the arbitrator(s) may convene a hearing
if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within sixty (60) days after the arbitrator’s appointment, the arbitrator(s) will select one
of the two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The decision of the arbitrator(s) shall be final,
binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both Proposed Terms or award any other relief or take any
other action. 
 11.3 Governing Law. This Agreement shall be governed by and construed under the substantive laws of the
State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

11.4 Award. Any award to be paid by one Party to the other Party as determined by the arbitrator(s) as set forth above under
Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the losing Party.
Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16, judgment may be entered upon the final
award in any United States District Court located in New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred for breach of
the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s) or any court or any other forum to award
consequential, incidental, special, punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or exemplary damages. The only damages
recoverable under this Agreement are direct compensatory damages. 
 11.5 Costs. Each Party shall bear its own legal
fees. The arbitrator(s) shall assess his or her costs, fees and expenses against the Party losing the arbitration. 

  
 46 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 11.6 Injunctive Relief. Nothing in this Article 11 will preclude either Party
from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during
any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties agree that a material breach by either Party of its obligations in Section 3.5 or
Article 7 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies otherwise available at law, including, without limitation, the recovery of
damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.5 or Article 7, and without further proof of irreparable harm other than this acknowledgement, such non-breaching Party shall be entitled to
seek (a) immediate equitable relief, specifically including, but not limited to, both interim and permanent restraining orders and injunctions, without bond, and (b) such other and further equitable relief as the court may deem proper
under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise limit a breaching Party’s opportunity to cure a material breach as permitted in accordance with Section 10.2. 

11.7 Confidentiality. The arbitration proceeding shall be confidential and the arbitrator(s) shall issue appropriate protective
orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrator(s) without
prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as required in connection with the enforcement of such award or
as otherwise required by applicable law. 
 11.8 Survivability. Any duty to arbitrate under this Agreement shall remain
in effect and be enforceable after termination of this Agreement for any reason. 
 11.9 Jurisdiction. For the purposes
of this Article 11, the Parties acknowledge their diversity and agree to accept the jurisdiction of any United States District Court located in New York for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and
for enforcing the agreements reflected in this Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts. 
 11.10 Patent Disputes. Notwithstanding any other provisions of this Article 11, and subject to the provisions of Section 6.2, any dispute, controversy or claim relating to the scope, validity,
enforceability or infringement of any Intrexon Patents shall be submitted to a court of competent jurisdiction in the country in which such Patent was filed or granted. 

  
 47 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 12 

GENERAL PROVISIONS 
 12.1 Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other or any other trade name or trademark of the other in
connection with the performance of this Agreement, except that (a) either Party may use the name of the other Party as required by regulations and in press releases accompanying quarterly and annual earnings reports approved by the
issuer’s Audit Committee of the Board of Directors, and (b) Soligenix may use the Intrexon Trademarks in accord with licenses and restrictions set forth herein. 
 12.2 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS
AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES
AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 
 12.3 Independent Parties. The Parties are not
employees or legal representatives of the other Party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be
interpreted as a joint venture, partnership, or business organization of any kind. 
 12.4 Notice. All notices, including
notices of address change, required or permitted to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly
confirms receipt of such transmission with the other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail,
postage prepaid, return receipt requested. All such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

 

			
	If to Intrexon:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: Chief Executive Officer
 Fax: (301) 556-9901

		
	with a copy to:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: Legal Department
 Fax: (301)
556-9902

  
 48 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

			
	If to Soligenix:	  	 Soligenix, Inc.
 29 Emmons
Drive, Suite C-10
 Princeton, NJ 08540

Attention: Chief Executive Officer
 Fax: (609)
452-6467

 12.5 Severability. In the event any provision of this Agreement is held to be invalid or
unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 
 12.6 Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 

12.7 Entire Agreement; Amendment. This Agreement, including any exhibits attached hereto, constitute the entire, final, complete
and exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement (including any prior confidentiality agreement between the Parties). All
information of Intrexon or Soligenix to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by such other Party under the obligations set forth
in Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 
 12.8 Non-assignability; Binding on Successors. Any attempted assignment of the rights or delegation of the obligations under this Agreement shall be void without the prior written consent of the
non-assigning or non-delegating Party; provided, however, that either Party may assign its rights or delegate its obligations under this Agreement without such consent (a) to an Affiliate of such Party or (b) to its successor in interest
in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets, provided that such assignee agrees in writing to assume and be bound by the
assignor’s obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators and permitted assigns of the Parties. Notwithstanding the
foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or substantially all of its assets (whether
this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of law (e.g., in the context of a reverse triangular merger)), 

  
 49 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
the intellectual property rights of such successor in interest or any of its Affiliates other than those licensed in this Agreement shall be automatically excluded from the rights licensed to the
other Party under this Agreement. 
 12.9 Force Majeure. Neither Party shall be liable to the other for its failure to
perform any of its obligations under this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including
without limitation earthquakes, governmental regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property,
whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 
 12.11
Non-Solicitation. During the Term and for a period of one (1) year following the end of the Term, neither Soligenix nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment
with, or hire any employee of the other Party or an individual who was employed by the other party within one (1) year prior to such solicitation, discussion, or hire, without the prior approval of such other Party. General employment
solicitations or advertisements shall not be considered direct or indirect solicitations, and are not prohibited under this Agreement. 
 12.12 Legal Compliance. The Parties shall review in good faith and cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws. 

12.13 Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile, PDF, or other means of
electronic communication), each of which taken together will constitute one and the same instrument, and any of the Parties hereto may execute this Agreement by signing any such counterpart. 

[Remainder of page intentionally left blank.] 

  
 50 

 REDACTED COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 IN WITNESS WHEREOF, the Parties
hereto have duly executed this Exclusive Channel Collaboration Agreement. 
  

									
	INTREXON CORPORATION	 		 	SOLIGENIX, INC.
					
	By:	 	 /s/ Donald P. Lehr
	 		 	By:	 	 /s/ Christopher J. Schaber

					
	Name:	 	Donald P. Lehr	 		 	Name:	 	Christopher J. Schaber, Ph.D.
					
	Title:	 	Chief Legal Officer	 		 	Title:	 	President and Chief Executive Officer

 SIGNATURE PAGE FOR EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

  
 51Exhibit 10.16

 Exhibit 10.16 
 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this
document has been filed separately with the Securities and Exchange Commission. 
 COLLABORATION AND LICENSE AGREEMENT

 THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of June 6, 2011 (the
“Effective Date”) is entered into between HALOZYME, INC., a California corporation (“Halozyme”) and INTREXON CORPORATION, a Virginia corporation (“Intrexon”). 

WHEREAS, Halozyme is the owner or exclusive licensee of certain patents, formulations and know-how related to the PH20 Drug (as defined
below); 
 WHEREAS, Intrexon is the owner or exclusive licensee of certain intellectual property related to the Intrexon
Biologic (as defined below); 
 WHEREAS, Intrexon may seek one or more drug designations in the United States or elsewhere for
products derived from or related to the Intrexon Biologic; and 
 WHEREAS, the parties desire to enter into a collaborative
relationship in which the parties will collaboratively develop, and Halozyme will license to Intrexon the right to commercialize, the Product in the Licensed Field in the Territory (each as defined below), all on the terms and conditions of this
Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the parties
hereby agree as follows: 
  

	 	1.	DEFINITIONS. 

 1.1
“Affiliate” shall mean, with respect to a party, any entity that controls or is controlled by such party, or is under common control with such party. For purposes of this definition, an entity shall be deemed to control another
entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting equity of another entity (or other comparable interest for an entity other than a corporation). 

1.2 “API” shall mean the bulk formulation of PH20 Drug [*****]. 

1.3 “API Specifications” shall mean the specifications for the API set forth in Schedule 1.3. 

1.4 “BLA/MAA” shall mean a Biologics License Application (“BLA”) submitted to the FDA or a Market
Authorization Application (“MAA”) submitted to the EMA or MHLW, or any supplemental filing to a BLA or MAA. 

1.5 “cGMP” shall mean the principles detailed in the United States Current Good Manufacturing Practices (21 CFR 200, 211
and 600), the “Rules Governing Medicinal Product in The European Community – Volume IV Good Manufacturing Practice for Medicinal Products,” and/or “Cooperative Manufacturing Arrangements for Licensed Biologics” FDA-CBER.

  
 1 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.6 “Clinical Trial” shall mean any human clinical trial in any country
the results of which are to evaluate or establish safety, efficacy or dosing, including without limitation pursuant to 21 CFR 312.21, et seq. A “Phase III Clinical Trial” shall mean a pivotal human clinical trial in any
country the results of which could be used to establish safety and efficacy of a Product as a basis for a BLA/MAA or that would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent. 

1.7 “CMO” shall mean contract manufacturing organization. 

1.8 “Collaboration Invention” shall mean any invention or discovery, whether or not patentable (including a
modification, improvement or new use), that is first conceived or reduced to practice pursuant to Halozyme’s activities, Intrexon’s activities or both parties’ joint activities that is related to the Intrexon Biologic, the PH20 Drug
and/or the combination of both, in each case during the term of this Agreement and in connection with work conducted under the Workplan. 
 1.9 “Collaboration Supported Patents” shall mean (a) all patent applications filed after the Effective Date which claim, and only to the extent it claims, a Collaboration Invention;
(b) all patents that have issued or in the future issue from any of the foregoing patent applications, including without limitation utility models, design patents and certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, renewals, re-examinations, extensions or term additions to any such patents and patent applications. 
 1.10 “Collaboration Supported PH20 Patents” shall mean all Collaboration Supported Patents to the extent claiming or covering PH20 Drug [*****] alone or in combination with any molecule
or biologic, but excluding the Collaboration Supported Product Patents. 
 1.11 “Collaboration Supported Product
Patents” shall mean all Collaboration Supported Patents to the extent claiming or covering a Collaboration Invention with respect to PH20 Drug [*****] combined with the Intrexon Biologic. 

1.12 “Collaboration Supported Intrexon Biologic Patents” shall mean all Collaboration Supported Patents to the extent
claiming or covering the Intrexon Biologic, but excluding the Collaboration Supported Product Patents. 
 1.13
“Confidential Information” shall mean all information and data that (a) is provided by one party to the other party under this Agreement, and (b) if disclosed in writing or other tangible medium is marked or identified as
confidential at the time of disclosure to the recipient, is acknowledged at the time of disclosure to be confidential, or otherwise should reasonably be deemed to be confidential. Notwithstanding the foregoing, Confidential Information of a party
shall not include that portion of such information and data which, and only to the extent, the recipient can establish by written documentation: (i) is known to the recipient as evidenced by its written records before receipt thereof from the
disclosing party, (ii) is disclosed to the recipient free of confidentiality obligations by a third person who has the right to make such disclosure, (iii) is or becomes part of the public domain through no fault of the recipient, or
(iv) the recipient can reasonably establish is independently developed by persons on behalf of recipient without use of the information disclosed by the disclosing party. 

  
 2 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.14 “cover” or “covering” as used in relation to a
patent or patent right shall include composition of matter claims as well as methods of manufacture or use. 
 1.15
“DMF” shall mean a Drug Master File filed with the FDA, EMA, MHLW or another foreign equivalent. 
 1.16
“EMA” shall mean the European Medicines Agency of the European Union, or the successor thereto. 
 1.17
“Excluded Fields” shall mean [*****]. 
 1.18 “Exclusive Biologic” shall mean, with respect to
the Exclusive Field, any molecule or biologic which (1) as of the Effective Date is currently in clinical development to evaluate such product’s safety or efficacy for use in the Exclusive Field, or is commercialized for use in the
Exclusive Field, and (2) after the Effective Date may at any time during the term of this Agreement be the subject of a clinical study specifically designed to evaluate such product’s safety or efficacy for use in the Exclusive Field.

 1.19 “Exclusive Field” shall mean genetic emphysema. 

1.20 “FDA” shall mean the United States Food and Drug Administration, or any successor entity thereto. 

1.21 “First Commercial Sale” shall mean the first sale of the Product by Intrexon, its sublicensee or their respective
Affiliates to customers who are not Affiliates in any country after all applicable marketing approvals (if any) have been granted by the applicable governing health authority. 
 1.22 “FTE” shall mean a full time equivalent of an employee for one calendar year. 
 1.23 “Fully Burdened Manufacturing Cost” shall mean Halozyme’s fully burdened cost to manufacture (or acquire from its third party manufacturer) and supply API, including without
limitation costs for testing, packaging, shipping and an allocable share of corporate and overhead costs. 
 1.24 “Fully
Burdened Workplan Cost” shall mean the cost to conduct the research and development activities to be conducted by Halozyme as set forth in the Workplan calculated on an FTE basis at a rate through the first [*****] years of the Agreement at
[*****] dollars ($[*****]) per FTE, subject to increase thereafter based on the Producer Price Index for Finished Goods Less Food and Energy (PPILFE), published by the United States Department of Labor in the monthly Labor Review. 

  
 3 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.25 “Grantback Patent” shall mean any issued patent owned or
controlled by Intrexon at any time during the term of this Agreement that claims the composition, manufacture or use of PH20 Drug [*****] alone or in combination with any other biologic or molecule, but not to the extent claiming the Intrexon
Biologic. 
 1.26 “Halozyme In-License” shall mean a license, sublicense or other agreement under which
Halozyme has acquired, or hereafter acquires, rights to the Licensed IP Rights. Schedule 1.26 sets forth a true and correct list as of the Effective Date of the Halozyme In-Licenses. 

1.27 “IND” shall mean an Investigational New Drug application or similar application required to commence human clinical
testing of a product submitted to the FDA, or its foreign equivalent. 
 1.28 “Intrexon Biologic” shall mean
that certain alpha-1 anti-trypsin molecule with the amino acid sequence set forth on Schedule 1.28, including any analogs, splice variants, glycoforms, truncated forms, muteins, fusions for extending half life or for purification
purposes, point mutations or other derivatives of such inhibitor, whether human or recombinant, provided in each case that (i) such molecule retains at least 25% of the specific activity of purified alpha-1 anti-trypsin molecule with the amino
acid sequence set forth in Schedule 1.28, and determined in a human pancreatic elastase assay (ENZO Neutrophil Elastase Colorimetric Drug Discovery Kit) (or such other assay as demonstrated by Intrexon to Halozyme’s reasonable
satisfaction to be scientifically valid), and (ii) such molecule does not have greater than 0.8 units of activity per milligram of protein, where a unit is the amount of C1-inhibitor activity present in one (1) milliliter of normal, human
plasma, as measured by the Behrichrom C-1 inhibitor assay (in accordance with the instructions provided with such assay) or such other assay as demonstrated by Halozyme to Intrexon’s reasonable satisfaction to be scientifically valid

 1.29 “Intrexon Subcutaneous Product” shall mean the Intrexon Biologic administered through a subcutaneous
mode of administration for use with any indication in the Licensed Field, but excluding the Product. 
 1.30 “Licensed
Field” shall mean the diagnosis, prevention, management or treatment of any disease state or condition in humans, but excluding the Excluded Fields. 
 1.31 “Licensed IP Rights” shall mean, collectively, the Licensed Know-How Rights, Licensed Patent Rights and Licensed Marks. 

1.32 “Licensed Know-How Rights” shall mean all of Halozyme’s rights (including Halozyme’s grantback rights
from third parties to the extent sublicensable) in all trade secret and other know-how relating to PH20 Drug [*****] that are necessary or useful to develop, obtain regulatory approval for, manufacture, commercialize or use Products in the Licensed
Field. 
 1.33 “Licensed Marks” shall mean those certain trademarks, trade names, designs and markings owned or
licensed by Halozyme and designated from time to time in writing by Halozyme for use by Intrexon under this Agreement in connection with the packaging, labeling, promotion and marketing of Products in the Licensed Field. 

  
 4 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.34 “Licensed Patent Rights” shall mean all of Halozyme’s rights
(including Halozyme’s grantback rights from third parties to the extent sublicensable) in (a) all patent applications heretofore or hereafter filed that claim or cover PH20 Drug [*****] alone or in combination with any other composition,
as necessary or useful to develop, obtain regulatory approval for, manufacture, commercialize or use Products in the Licensed Field, (b) all patents that have issued or in the future issue from any of the foregoing patent applications,
including without limitation utility models, design patents and certificates of invention, and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such patents and patent applications.
For clarity, Licensed Patents Rights include Collaboration Supported PH20 Patents. 
 1.35 “MHLW” shall mean
the Ministry of Health, Labour and Welfare of Japan, or the successor thereto. 
 1.36 “Net Sales” shall mean
the gross sales price of the Product invoiced by Intrexon, its sublicensee or their respective Affiliates to customers who are not Affiliates (or who are Affiliates but are the end users of the Product) less, to the extent actually paid or accrued
by Intrexon, its sublicensee or their respective Affiliates (as applicable): (a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such customers for Product; (b) packaging, freight and insurance costs
incurred by Intrexon, its sublicensee or their respective Affiliates (as applicable) in transporting Product to such customers; (c) cash, quantity and trade discounts, rebates, assessments and other price reductions for Product given to such
customers under price reduction programs that are consistent with price reductions given for similar products by Intrexon, its sublicensee or their respective Affiliates (as applicable); (d) sales, use, value-added and other direct taxes
incurred on the sale of Product to such customers; (e) customs duties, surcharges and other governmental charges incurred in exporting or importing Product to such customers; (f) the amount of any [*****] up to a maximum of [*****] as
calculated under clauses (a) – (e) above on a quarterly basis; and (g) any adjustments substantially similar to any of the foregoing. 
 1.37 “PH20 Drug” shall mean the active compound, recombinant human PH20 hyaluronidase (i.e. a truncated form of native human PH20 hyaluronidase consisting of residues 36-482, inclusive,
of the native human PH20 hyaluronidase). 
 1.38 “ [*****]” shall mean a [*****] that consists of any
improvement or enhancement to [*****] and intended to [*****]. 
 1.39 “Prior Collaborations” shall have the
meaning ascribed to it in Section 2.2.1. 
 1.40 “Product” shall mean a product that includes (a) the
Intrexon Biologic (and, except as otherwise set forth below, no other active pharmaceutical ingredients), and (b) PH20 Drug supplied by Halozyme [*****] to Intrexon pursuant to this Agreement 

([*****]), as an active ingredient/excipient for enhancing the dispersion and/or absorption of the Intrexon Biologic, in any liquid injectable
formulation, and/or any 

  
 5 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
lyophilized formulation, which product is promoted, marketed and sold in a co-formulation (e.g., pre-formulated together in a single solution in a single container, in a single package with a
single label at a single price). For the avoidance of doubt, the addition of any excipient or adjuvant to the product shall not render such product outside the definition of Product. 

1.41 “Royalty Term” shall mean, with respect to each country, the period equal to the longer of (a) if, at the time
of the First Commercial Sale of Product in such country, the use, offer for sale, sale or import of Product in such country would infringe a Valid Claim, the term for which such Valid Claim remains in effect and would be infringed, and
(b) ten (10) years following the date of the First Commercial Sale of Product in such country. 
 1.42
“SEC” shall have the meaning ascribed to it in Section 2.1.1. 
 1.43 “Valid Claim” shall
mean a claim of an issued and unexpired patent included within the Licensed Patent Rights or the Collaboration Supported Product Patents, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. 

1.44 “Workplan” shall have the meaning set forth in Section 5.1.2. 

 

	 	2.	REPRESENTATIONS, WARRANTIES AND COVENANTS. 

 2.1 By Each Party. Each party represents and warrants to the other party as follows: 
 2.1.1 Organization. Such party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized. 

2.1.2 Authorization and Enforcement of Obligations. Such party (a) has the requisite power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder; and (b) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement
has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 
 2.1.3 Consents. All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to be obtained by such party in connection with this
Agreement have been obtained. 
 2.1.4 No Conflict. The execution and delivery of this Agreement and the performance of
such party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b) do not conflict with, or constitute a default under, any contractual
obligation of such party. 
 2.1.5 No Debarment. In the course of the development of the Product, neither party shall
use, during the Term, any employee or consultant who has been debarred by any regulatory authority, or, to the best of such party’s knowledge, is the subject of debarment proceedings by a regulatory authority. 

  
 6 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 2.2 By Halozyme. Halozyme further represents and warrants to Intrexon as follows:

 2.2.1 Licensed Patent Rights; Licensed IP Rights. As of the Effective Date, the Licensed Patent Rights have not been
held by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. As of the Effective Date, except as expressly set forth under the heading “Risks Related To Our Industry” in Halozyme’s Form 10-K for the
year ending December 31, 2010 filled with the Securities and Exchange Commission (“SEC”), Halozyme has not received written notice of any claim or litigation by any third party alleging that any of the Licensed Patent Rights
are invalid or unenforceable. Halozyme has the right to grant the licenses under the Licensed IP Rights pursuant to this Agreement. 
 (a) Schedule 2.2.1(a) sets forth a true and complete list of all Licensed Patent Rights as of the Effective Date, and indicates the current status, date and country of filing and issuance.

 (b) [*****] 
 (c) Neither Halozyme nor any of its Affiliates has received any written notice from any person that the use or practice of the Licensed Patent Rights or Licensed Know-How Rights infringes or
misappropriates the intellectual property rights of a third party. 
 (d) [*****] 

(e) All current and former employees and consultants of Halozyme and its Affiliates who are or have been substantively involved in the
design, review, evaluation or development of the Licensed Patent Rights or Licensed Know-How Rights have executed written contracts or are otherwise obligated to protect the confidential status and value thereof and to vest in Halozyme or its
Affiliates exclusive ownership of the Licensed Patent Rights and Licensed Know-How Rights. 

  
 7 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (f) The Halozyme In-Licenses, as set forth on Schedule 1.26, sets forth a
true and complete list of all agreements to which Halozyme is a party that are necessary or useful for the manufacture, use, sale or importation of PH20 Drug, copies of which have been provided by Halozyme to Intrexon, subject to redaction of
confidential or proprietary information provided, however, that such redaction does not unreasonably interfere with Intrexon’s understanding of the relevant sections of such agreements. Halozyme has fulfilled all of its obligations and is not
in breach or default under such agreements and has not waived or allowed to lapse or terminate any of its rights thereunder. 

2.2.2 Halozyme In-Licenses. Halozyme has not received notice of breach or termination of the Halozyme In-Licenses. 

2.2.3 SEC Reports. To Halozyme’s knowledge, neither Halozyme’s Report on Form 10-K for the year ended December 31,
2010, nor any other document filed by Halozyme with the SEC since March 11, 2011, contained a misstatement of a material fact, or failed to state a material fact required to be stated therein or necessary to make the statements made therein not
misleading, as of the date such filing was made, in each case relating to the Licensed Patent Rights and Licensed Know-How Rights. 
 2.2.4 API Specifications. The API Specifications set forth on Schedule 1.3 hereto are consistent with the specifications for API to be provided under the Prior Collaborations. Halozyme’s
present manufacturing process has produced PH20 Drug with qualities that meet the API Specifications. 
 2.3 DISCLAIMER OF
WARRANTIES. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH ABOVE OR IN SECTION 7.7, HALOZYME MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, REGARDING THE LICENSED IP RIGHTS, INCLUDING WITHOUT LIMITATION, ANY REPRESENTATION OR WARRANTY
REGARDING VALIDITY, ENFORCEABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT. 
  

	 	3.	LICENSE. 

 3.1 License
Grant to Intrexon. 
 3.1.1 On the terms and conditions of this Agreement, Halozyme hereby grants to Intrexon an exclusive
worldwide license under the Licensed IP Rights (with the limited right to sublicense pursuant to Section 3.1.2) to develop, make, have made, use, offer for sale, sell and import Products for use in the Licensed Field. Except as expressly set
forth in this Agreement, Intrexon shall not use the Licensed IP Rights for any other use. 
 3.1.2 Intrexon shall have the
right to grant sublicenses to (a) third parties solely for the purpose of developing, manufacturing or commercializing such Product in each case jointly with, or for the benefit of, Intrexon and (b) Affiliates. Intrexon shall provide
Halozyme with a copy of each sublicense referenced in clause (a) and prompt notice of each sublicense referenced in clause (b), subject to redaction of confidential or proprietary information provided, however, that such redaction does not
unreasonably interfere with Halozyme’s understanding of the relevant sections of such sublicenses. Any such sublicense 

  
 8 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
shall be subject and subordinate to the terms and conditions of this Agreement. Intrexon hereby represents that it has the power to bind its Affiliates to the terms and conditions set forth in
this Agreement and any Affiliate that receives a sublicense shall be bound by the terms and conditions of this Agreement as if such Affiliate was an original signatory to this Agreement. Notwithstanding the foregoing, Intrexon shall remain liable
for a breach of this Agreement by its Affiliate and shall remain responsible for all payments due to Halozyme hereunder. 
 3.2
No Implied Licenses. Only licenses and rights expressly granted herein shall be of legal force and effect. No license or other right shall be created hereunder by implication, estoppel or otherwise. 

3.3 Exclusivity. 
 3.3.1 Commencing on the Effective Date, neither Halozyme nor any of its Affiliates shall grant to any third party any right to develop, make, have made, use, offer for sale, sell or import any product
that consists of PH20 Drug [*****] together with an Exclusive Biologic for use in the Exclusive Field. 
 3.3.2 Commencing on
the Effective Date, neither Halozyme nor any of its Affiliates shall grant to any third party any right to develop, make, have made, use, offer for sale, sell or import any product that consists of PH20 Drug [*****] together with the Intrexon
Biologic (with or without any additional active pharmaceutical ingredients) for use in the Licensed Field. 
 3.3.3 Neither
Halozyme nor its Affiliates shall sell or enter into any agreement with any third party to sell PH20 Drug [*****] with an Exclusive Biologic in a kit (i.e., the PH20 Drug [*****] and the biologic or molecule are in separate containers, but packaged
together and at a single price) for use in the Exclusive Field. 
 3.3.4 Halozyme shall include in any future agreements with a
third party to develop, make, have made, use, offer for sale, sell or import any product that consists of PH20 Drug [*****] (including products sold as a kit with PH20 Drug or [*****] a covenant prohibiting such third party from using such product
in the Exclusive Field. 
 3.3.5 For the avoidance of doubt, nothing in this Agreement shall restrict Halozyme from granting
rights to a Third Party for PH20 Drug [*****] combined with an Exclusive Biologic (except for the Intrexon Biologic) outside the Exclusive Field. 
 3.4 Excluded Fields. Intrexon shall not seek regulatory approval of the Product, or use or commercialize the Product, for use in any of the Excluded Fields. 

 

	 	4.	FINANCIAL TERMS. 

 4.1
License Fee. Within [*****] business days of the Effective Date, Intrexon shall pay to Halozyme the nonrefundable and noncreditable initial license fee of nine million dollars ($9,000,000). 

  
 9 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 4.2 Exclusivity Fee. Commencing with the first anniversary of the Effective Date,
and continuing with each successive anniversary until the initiation of the first Phase III Clinical Trial for the Product, Intrexon shall pay to Halozyme the non-refundable and non-creditable exclusivity fee of one million dollars ($1,000,000).

 4.3 Milestone Payments. 
 4.3.1 Within thirty (30) days following the achievement of each of the following development milestones, Intrexon shall give written notice to Halozyme and shall pay to Halozyme the corresponding
non-refundable and non-creditable milestone payments: 
 (i) $[*****] [*****]; 

(ii) $[*****] [*****]; 
 (iii) $[*****] [*****]; 
 (iv) $[*****] [*****]; 

(v) $[*****] [*****]; 
 (vi) $[*****] [*****]; 
 (vii) $[*****] [*****]; 

(viii) $[*****] [*****]; 
 (ix) $[*****] [*****]; 
 (x) $[*****] [*****]; 

(xi) $[*****] [*****]; 
 (xii) $[*****] [*****] 
 (xiii) $[*****] [*****]. 

  
 10 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 If for whatever reason (other than due to a breach by Intrexon) a milestone payment set forth above is
not paid for a Product and the subsequent development event that corresponds to the same indication and to the same country or jurisdiction is achieved for such Product (for example, doing a [*****]), then both the then-achieved milestone payment
and the prior unpaid milestone payment shall be payable at the time the then-achieved milestone payment is made. Except for those milestone payments that are due for each disease or indication other than the Exclusive Field, each milestone payment
shall be payable only one (1) time, regardless of the number of times that the corresponding event is achieved. If the development of a Product is terminated under this Agreement (“Terminated Product”) for any reason and
another Product is developed under this Agreement and then achieves an event giving rise to a milestone payment, such milestone payment shall not be made if it had previously been made with respect to the Terminated Product. 

4.4 Royalties. 
 4.4.1 During the applicable Royalty Term, Intrexon shall pay to Halozyme royalties on annual Net Sales by Intrexon, its sublicensees and their respective Affiliates in any country equal to
(a) [*****] of the first [*****] dollars ($[*****]) of such annual Net Sales, (b) [*****] of such annual Net Sales in excess of [*****] dollars ($[*****]) up to and including [*****] dollars ($[*****]), (c) [*****] of such annual Net
Sales in excess of [*****] dollars ($[*****]) up to and including [*****] dollars ($[*****]), and (d) eleven percent (11%) of such annual Net Sales in excess of [*****] dollars ($[*****]). In any country where either (i) there is no
Valid Claim that would be infringed by the making, using, selling, offering for sale or importation of the Product (for clarity, a Valid Claim may be included in the Licensed Patent Rights or the Collaboration Supported Product Patents, so long as
it would be infringed by the making, using, selling, offering for sale or importation of the Product in such country), or [*****], then the foregoing royalty rate in such country shall be reduced by [*****] with respect to applicable Net Sales in
such country. 
 4.4.2 If Intrexon, its sublicensees or their respective Affiliates sells a Product to a third party who also
purchases other products or services from Intrexon, its sublicensees or their respective Affiliates, and Intrexon, its sublicensees or their respective Affiliates discounts the purchase price of such Product to a greater degree than it generally
discounts the price of its other products or services to such customer, then in such case the Net Sales for the sale of such Product to such third party shall equal the arm’s length price that third parties would generally pay for the Product
alone when not purchasing any other product or service from Intrexon, its sublicensee or their respective Affiliates. For purposes of this provision, “discounting” includes establishing a price for a Product at a discount of [*****] or
more from the average sales price for the applicable country of end use or for the applicable region if sales are conducted on a regional basis. 

  
 11 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 4.5 API Price. For all API supplied by Halozyme under Article 7, Intrexon
shall pay to Halozyme a price equal to [*****] percent ([*****]%) of the Fully Burdened Manufacturing Cost to Halozyme to manufacture (or have manufactured), store and supply API. As of the date of this Agreement, the Fully Burdened
Manufacturing Cost to Halozyme of the API is reasonably estimated at $[*****]/milligram. Halozyme shall invoice Intrexon for all API upon shipment in accordance with Article 7, and Intrexon shall pay each such invoice unless contested within
[*****] days after receipt. 
 4.6 Royalty Reports. 

4.6.1 Within [*****] days after the end of the first, second and third calendar quarters of each calendar year and within [*****]
days after the end of the fourth quarter during each calendar year, commencing with the calendar quarter in which there is a first commercial sale of a Product, to the extent such information is reasonably available, Intrexon shall furnish to
Halozyme a written report showing in reasonably specific detail, on a country-by-country basis, (a) the quantity and aggregate gross sales of all Products sold by Intrexon, its sublicensees and their respective Affiliates during such calendar
quarter and the calculation of Net Sales from such gross sales; (b) the calculation of the royalties, if any, which shall have accrued based upon such Net Sales; (c) the withholding taxes, if any, required by law to be deducted with
respect to such sales; and (d) the exchange rates, if any, used in determining the amount of United States dollars. 

4.6.2 With respect to sales of Products invoiced in United States dollars, all such amounts shall be expressed in United States dollars.
With respect to sales of Products invoiced in a currency other than United States dollars, all such amounts shall be expressed both in the currency in which the sale is invoiced and in the United States dollar equivalent. The United States dollar
equivalent shall be calculated using the average of the exchange rates (local currency per US$1) published in The Wall Street Journal, Western Edition, under the heading “Currency Trading” on the last business day of each month in
the applicable calendar quarter. All royalties payable hereunder shall be calculated based on Net Sales expressed in United States dollars. 
 4.6.3 Intrexon shall keep, to the extent such information is reasonably available, complete and accurate records in sufficient detail to properly reflect all gross sales and Net Sales and to enable the
royalties payable to be determined. 
 4.6.4 All royalties shown to have accrued by each royalty report provided under this
Section 4.6 shall be payable on the date such royalty report is due. Payment of royalties in whole or in part may be made in advance of such due date. 
 4.7 Audits. 
 4.7.1 Upon the written request of Halozyme and not more than
once in every two years, Intrexon shall permit an independent certified public accounting firm of nationally recognized standing, selected by Halozyme and reasonably acceptable to Intrexon, to have access during normal business hours to such records
of Intrexon as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any year ending not more 

  
 12 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
than [*****] months prior to the date of such request and which have not previously been audited. The accounting firm shall disclose to Halozyme only whether the reports are correct and the
specific details of any discrepancy, but no other information shall be shared. If such accounting firm concludes that additional royalties were owed during the audited period, or that excess royalties were paid during the audited period, Intrexon
shall pay such additional royalties, or Halozyme shall provide Intrexon with a credit for such excess royalties, as the case may be, within [*****] days of the date Halozyme delivers to Intrexon such accounting firm’s written report so
concluding; provided, that, in the case of a credit, if Intrexon is unable to use the full amount of such credit within [*****] months from the date of such report, then Halozyme shall promptly pay to Intrexon the unused amount of such credit. The
fees charged by such accounting firm shall be paid by Halozyme; provided, however, if the audit discloses that the royalties payable by Intrexon for such period are more than [*****] percent ( [*****]%) of the royalties actually paid for such
period, then Intrexon shall pay the reasonable fees and expenses charged by such accounting firm. Halozyme shall treat all financial information subject to review under this Section 4.7.1 as confidential, and shall cause its accounting firm to
retain all such financial information in confidence and shall be liable to Intrexon for any improper disclosure by its accounting firm. 
 4.7.2 Upon the written request of Intrexon and not more than once in every two years, Halozyme shall permit an independent certified public accounting firm of nationally recognized standing, selected by
Intrexon and reasonably acceptable to Halozyme, to have access during normal business hours to such records of Halozyme as may be reasonably necessary to verify the accuracy of each of the API transfer price and the Workplan costs hereunder for any
year ending not more than [*****] months prior to the date of such request and which have not previously been audited. The accounting firm shall disclose to Intrexon only whether the API transfer price and/or the Workplan cost was correct and the
specific details of any discrepancy, but no other information shall be shared. If such accounting firm concludes that Halozyme overcharged for the API transfer price and/or the Workplan cost during the audited period, or that Halozyme undercharged
for the API transfer price and/or the Workplan cost during the audited period, Halozyme shall provide Intrexon with a credit for such overcharge, or Intrexon shall make an additional payment in respect of such undercharge, within [*****] days of the
date Intrexon delivers to Halozyme such accounting firm’s written report so concluding; provided, that, in the case of a credit, if Intrexon is unable to use the full amount of such credit within [*****] months from the date of such report,
then Halozyme shall promptly pay to Intrexon the unused amount of such credit. The fees charged by such accounting firm shall be paid by Intrexon; provided, however, if the audit discloses that the API transfer price and/or the Workplan cost charged
by Halozyme for such period was more than [*****] percent ([*****]%) of the API transfer price and/or the Workplan cost, as the case may be, actually due for such period, then Halozyme shall pay the reasonable fees and expenses charged by such
accounting firm. Intrexon shall treat all financial information subject to review under this Section 4.7.2 as confidential, and shall cause its accounting firm to retain all such financial information in confidence and shall be liable to
Halozyme for any improper disclosure by its accounting firm. 
 4.8 Withholding Taxes. Intrexon shall be entitled to
deduct from the royalty payments otherwise due to Halozyme hereunder the amount of any withholding taxes, value-added taxes or other taxes, levies or charges with respect to such royalty payments that are

  
 13 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
required to be withheld by Intrexon. Intrexon shall pay to the appropriate governmental authority on behalf of Halozyme such taxes, levies or charges that are withheld. Intrexon shall use
reasonable efforts to take such action as may be reasonably requested by Halozyme, and at Halozyme’s cost, to minimize any such taxes, levies or charges required to be withheld on behalf of Halozyme by Intrexon, provided that such actions do
not, or could not reasonably be expected to, adversely affect or impact Intrexon or any of its Affiliates. Intrexon promptly shall deliver to Halozyme proof of payment of all such taxes, levies and other charges, together with copies of all
communications from or with such governmental authority with respect directly related thereto. 
 4.9 Payment Method. All
payments by Intrexon to Halozyme hereunder shall be in United States Dollars in immediately available funds (or funds that will be available on or prior to the date such payment is due) and shall be made by wire transfer to such bank account as
designated from time to time by Halozyme to Intrexon. Except with respect to any amounts disputed in good faith, any late payments due hereunder shall bear interest at the rate of [*****]% per month, or the maximum allowable by law if less.

  

	 	5.	PRODUCT DEVELOPMENT AND COMMERCIALIZATION. 

 5.1 Responsibility. 
 5.1.1 Except as otherwise set forth in this
Section 5.1, Intrexon shall be solely responsible, at its sole cost, for conducting the development, manufacture, regulatory approval and commercialization of Products, and shall own all clinical data, regulatory applications, filings,
approvals and licenses for each Product. 
 5.1.2 Intrexon shall engage Halozyme to conduct development and regulatory work for
the PH20 Drug component of each Product and for providing technical assistance regarding the development of each Product. All such activities by Halozyme shall be conducted at the reasonable request of Intrexon pursuant to a mutually acceptable
written workplan that is customary in the industry (the “Workplan”). Following the end of each calendar quarter, Halozyme shall invoice Intrexon for the Fully Burdened Workplan Cost to Halozyme to conduct such activities, and
Intrexon shall pay each such invoice within [*****] days after receipt. 
 5.1.3 Halozyme shall provide Intrexon with a full
dossier for the PH20 Drug for Intrexon’s use in BLA/MAA filings. Such dossier will include chemistry manufacturing and controls sections and pre-clinical pharmacology and toxicology sections. Upon written request from Intrexon, Halozyme will
file a DMF for the PH20 Drug as promptly as practicable. Halozyme shall own the DMF for the PH20 Drug component of each Product. Intrexon shall have the right to cross-reference such DMF. In countries where this is not feasible, Halozyme shall
provide Intrexon, at Intrexon’s cost, with such information in Halozyme’s control regarding the PH20 Drug component of each Product as is reasonably necessary for Intrexon to include in the applicable regulatory applications for such
Product. Halozyme shall promptly notify Intrexon of any changes to the dossier or DMF for the PH20 Drug. 

  
 14 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 5.1.4 Promptly following the Effective Date, each party shall appoint a person to act
as its alliance manager to coordinate its business activities under this Agreement, and a technical leader to coordinate its technical activities under this Agreement. Each party shall notify in writing the other party as soon as practicable upon
making, and changing, any of these appointments. The alliance managers shall be the primary business contacts, and the technical leaders shall be the primary technical contacts, between the parties with respect to their respective activities under
this Agreement. Each party shall maintain an alliance project team, with an equal number of representatives as mutually agreed upon by the parties, that consists of at least the alliance manager and technical leader. The purpose of the alliance
project team shall be to exchange information and oversee the strategic, technical and operation aspects of the alliance. The alliance project team will have monthly meetings (which will be in person at least once per quarter), unless otherwise
agreed to. Among its other responsibilities, the alliance project team shall approve the Workplan, and all amendments thereto. Notwithstanding the foregoing, but subject to Article 6, Intrexon shall have final decision-making authority with
respect to the development, manufacturing, regulatory approval and commercialization of the Product. Each party shall be responsible for its own costs in connection with the meetings of the alliance project team. Within [*****] weeks after each
meeting of the alliance project team, one party (alternating from meeting to meeting) shall prepare and provide the other party with written minutes of the discussions, decisions and action items from such meeting which shall be subject to the
reasonable approval and comment of the other party. 
 5.1.5 In addition to Section 5.1.3, Intrexon may request Halozyme
to provide authorization for regulatory agencies cross-reference appropriate regulatory filings previously made by Halozyme or its Affiliates regarding PH20 Drug which is necessary with respect to obtaining regulatory approval for any Product.
Halozyme will not unreasonably withhold letters of authorization. 
 5.2 Diligence Efforts. 

5.2.1 Intrexon shall [*****] to [*****] and following such approval, [*****] to [*****]. For purposes of this Section 5.2, [*****].

 5.2.2 Neither Intrexon nor any of its Affiliates shall develop itself, or obtain a license from or otherwise collaborate
with a third party to develop an Intrexon Subcutaneous Product. 
 5.2.3 If Intrexon permanently abandons, or permanently
ceases, development, use or commercialization of, the Product in any indication within the Licensed Field, then Intrexon shall promptly deliver written notice to Halozyme of its decision therefore, and the parties shall remove such indication from
the Licensed Field. 

  
 15 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 5.3 Research and Development Reports. 

5.3.1 Intrexon shall keep complete and accurate records of its activities conducted under Section 5.1.1 of this Agreement and the
results thereof. Within [*****] days after the end of each calendar year until the First Commercial Sale in the United States of a Product, Intrexon shall prepare and provide Halozyme with a reasonably detailed written report of the activities
conducted under this Agreement, and the results thereof, through such date of such report, to develop and obtain regulatory approvals to market Products. 
 5.3.2 Halozyme shall keep complete and accurate records of its activities conducted under Section 5.1.2 of this Agreement and the results thereof. Within [*****] days after the end of each calendar
year until the First Commercial Sale in the United States of a Product, Halozyme shall prepare and provide Intrexon with a reasonably detailed written report of the activities conducted under this Agreement, and the results thereof, through such
date of such report, to develop and obtain regulatory approvals to market Products. 
 5.4 Trademarks. 

5.4.1 To the extent allowed under applicable law, Intrexon, its sublicensee or their respective Affiliates shall have the right to
determine the names and trademarks to use in connection with the promotion, marketing and sale of Products, and shall own and maintain such trademarks for use in connection with the promotion, marketing and sale of Products; provided, however, that,
to the extent legally permissible and commercially practicable, Intrexon shall include on all packaging, labeling and marketing and promotional materials regarding any Product the name HALOZYME, and the mark ENHANZE (or such other mark reasonably
requested by Halozyme) as a secondary mark, reasonably identifying that such product incorporates technology of Halozyme. The foregoing obligation shall exist so long as such marks are valid in the applicable country of sale. Nothing in this
Agreement shall create an obligation on Halozyme to register or otherwise maintain in force any marks. Halozyme shall promptly inform Intrexon, upon Intrexon’s reasonable request, as to whether the marks requested for inclusion by Halozyme are
properly registered in the applicable country of sale (with any necessary recordation or maintenance fees accounted for) and whether, to Halozyme’s knowledge, the requested marks have been determined by a governmental authority to be invalid or
unenforceable. 
 5.4.2 Except as otherwise set forth above, Intrexon, its sublicensees and their respective Affiliates shall
not (a) use any of Halozyme’s trademarks, or any mark or name confusingly similar thereto, as part of a corporate or business name or in any other manner, or (b) register any trade mark or trade name (including any company name) which
is identical to or confusingly similar to or incorporates any trade mark or trade name which Halozyme or any associated company owns or claims rights in. Any goodwill associated with any of Halozyme’s names or marks affixed or applied or used
in connection with Products shall accrue to the sole benefit of Halozyme. 

  
 16 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

	 	6.	REGULATORY MATTERS. 

 6.1
Notices. Except as otherwise set forth in this Agreement, Intrexon shall not communicate with the FDA or the governing health authorities of any country solely regarding the PH20 Drug incorporated into the Product without the prior consent of
Halozyme. If the FDA or the governing health authorities of any country initiates any oral communication with Intrexon solely regarding the PH20 Drug incorporated into the Product, Intrexon shall have the right to respond to such communication to
the extent reasonably necessary or appropriate under the circumstances; provided, however, that (a) Intrexon shall use reasonable efforts to limit the communications solely regarding the PH20 Drug incorporated into the Product that are
conducted without the participation of Halozyme; (b) promptly thereafter, Intrexon shall provide Halozyme with written notice thereof in reasonably specific detail describing the communications solely regarding the PH20 Drug incorporated into
the Product; and (c) Intrexon promptly shall provide Halozyme with copies of all minutes and other materials resulting therefrom (redacting any information that is confidential or proprietary, that does not relate to the PH20 Drug, or that it
is unable to legally disclose). Intrexon promptly shall provide Halozyme with copies of all written communications from the FDA or the governing health authorities of any country solely regarding the PH20 Drug incorporated into the Product
(redacting any information that is confidential or proprietary, that does not relate to the PH20 Drug, or that it is unable to legally disclose). With respect to any filing, communication or other submission with the FDA or the governing health
authorities of any country solely regarding the PH20 Drug incorporated into the Product, (a) Intrexon shall provide Halozyme with an advance copy of the reasonably complete draft thereof; (b) Halozyme shall have a reasonable opportunity to
review, comment and consult on such draft; (c) the parties shall discuss Halozyme’s comments solely regarding the PH20 Drug incorporated into such Product; (d) Intrexon shall in good faith consider the reasonable comments of Halozyme
solely regarding the PH20 Drug incorporated into such Product; and (e) Halozyme shall promptly respond to any inquiry from the FDA or the governing health authorities of any country that initiated communication concerning the PH20 Drug
incorporated into the Product, shall keep Intrexon reasonably informed of the subject of such communications, and shall provide Intrexon with copies of any minutes of any such proceedings to the extent such minutes relate to the Product or the
Intrexon Biologic. Halozyme shall keep Intrexon updated with respect to the regulatory strategy for the PH20 Drug incorporated into each Product and the consistency thereof with, or any differences from, Halozyme’s regulatory strategy for
Halozyme’s proprietary recombinant human PH20 hyaluronidase technology. Notwithstanding the foregoing, Intrexon shall have the sole right to communicate with the FDA or the governing health authorities of any country regarding the Intrexon
Biologic. 
 6.2 Results. Intrexon shall promptly inform Halozyme in writing, in reasonably specific detail, of any
material data, results or other information from each preclinical study or human clinical trial of a Product related to the PH20 Drug component of such Product. Halozyme shall promptly inform Intrexon in writing of any regulatory communication that
is received, or of any data, results or other information of which it becomes aware, relating to the PH20 Drug alone or as a component of a Product that may impact the safety or efficacy of a Product; provided, however, that neither party will be
required to disclose any data, results or other information (other than safety information) that will result in a breach of any confidentiality obligations with a third party. Each party acknowledges that information exchanged under this provision
may contain material, nonpublic information, a party’s awareness of which could prohibit that party from (1) buying or selling securities (stock, options, etc.) until after the information has been disclosed to the public and absorbed by
the market, and (2) passing the information on to anyone who may buy or sell securities. 

  
 17 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 6.3 Adverse Event Reporting. Each party shall promptly notify the other party of
any information that comes to such party’s attention concerning any serious or unexpected adverse event, injury, toxicity or sensitivity reaction, or any unexpected incidence, and the severity thereof, associated with the clinical uses,
studies, investigations, tests and marketing of PH20 Drug, the Intrexon Biologic or the Product. For purposes of this Section 6.3, “serious” shall mean an experience which (a) results in the death, a persistent or significant
incapacity or substantial disruption of the ability to conduct normal life functions, in-patient hospitalization or prolongation of hospitalization, or (b) is a congenital anomaly, the result of an overdose or life threatening (only if
unrelated to primary disease); and “unexpected” shall mean (x) for a nonmarketed Product, an experience that is not identified in nature, severity or frequency in the current clinical investigator’s confidential information
brochure, and (y) for a marketed product, an event which is not listed in the current labeling for such product, and includes an event that may be symptomatically and pathophysiologically related to an experience listed in the labeling but
differs from the event because of increased frequency or greater severity or specificity. Each party further shall immediately notify the other party of any information received regarding any threatened or pending action by an agency that may affect
the safety and efficacy claims of the Product. Upon receipt of any such information, the parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action; provided, however, that nothing
contained herein shall restrict either party’s right to make a timely report of such matter to any government agency or take other action that it deems to be appropriate or required by applicable law, regulation or court order. Each party shall
take all reasonable steps to protect the confidentiality of any patient health and medical information that it has access to and to comply with applicable state and federal privacy laws, as such laws apply to such party. 

 

	 	7.	SUPPLY OF API. 

 7.1
Manufacture and Sale. On the terms and conditions of this Article 7, Halozyme shall manufacture (or have manufactured), sell and deliver to Intrexon all API required by Intrexon, its sublicensees and their respective Affiliates for use
in the preclinical development, clinical development and commercialization of the Products, and Intrexon shall purchase from Halozyme all quantities of API required by Intrexon, its sublicensees and their respective Affiliates for use in the
preclinical development, clinical development and commercialization of the Products. Intrexon, its sublicensees and their respective Affiliates shall use such API supplied by Halozyme solely for the development, manufacture and commercialization of
Products pursuant to this Agreement. 
 7.2 Manufacturing Practices. 

7.2.1 Halozyme shall manufacture, or have manufactured, API under this Article 7 in conformity with the API Specifications and in
accordance with all applicable laws and regulations. The API Specifications shall not be amended without the prior written consent of both parties. Halozyme shall notify Intrexon in the event it agrees to modify the specifications for PH20 Drug
being provided to any of its other licensees. 

  
 18 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 7.2.2 Unless the parties otherwise mutually agree or except as otherwise contemplated
by this Agreement, Halozyme shall manufacture, or have manufactured, API under this Article 7 in accordance with cGMP as it may be in effect at the time. 
 7.2.3 Subject to Section 7.2.1, Halozyme shall [*****]. 
 7.2.4 Intrexon
shall have the right, at its sole expense, to audit Halozyme and its CMO of PH20 Drug for compliance with applicable laws and regulations and GMP on reasonable notice during normal business hours and not more than once in each calendar year, subject
to reasonable confidentiality obligations. 
 7.2.5 Halozyme shall provide Intrexon with certificates of analysis for all API
supplied hereunder based upon a reference standard established by Halozyme in accordance with all applicable rules and regulations and reasonably acceptable to Intrexon. 
 7.2.6 Upon the reasonable request of Intrexon, Halozyme shall provide Intrexon with such information, including analytical and manufacturing documentation, batch records for API and stability data, in
each case requested by Intrexon regarding quality control of API supplied under this Article 7. 
 7.2.7 All information
disclosed or obtained pursuant to this Article 7 shall be Confidential Information of Halozyme. 
 7.3 Forecasts and
Orders. 
 7.3.1 Not less than [*****] days prior to the first day of each calendar quarter (commencing with the first
calendar quarter in which Intrexon, its sublicensees or their respective Affiliates order API from Halozyme hereunder), Intrexon shall prepare and provide Halozyme with a written forecast of its good faith estimated requirements for API under this
Section 7.3 for each of the subsequent [*****] calendar quarters. Intrexon shall not (a) increase or decrease the quantity estimated for the [*****] quarterly period of each forecast from the quantity estimated for the [*****] quarterly
period of the previous forecast, (b) increase or decrease the quantity estimated for the [*****] quarterly periods of each forecast by more than [*****] percent ([*****]%) of the quantity estimated for the [*****] quarterly periods of the
previous forecast, respectively, without the prior express written consent of Halozyme. The quantities estimated for the [*****] quarterly periods of each forecast shall be non-binding, and for planning purposes only. 

7.3.2 Intrexon shall be required to purchase [*****] of the quantity forecasted for each API under this Section 7.3 for the first
and second quarterly periods of each forecast under Section 7.3.1. 
 7.3.3 Halozyme shall be required to supply the
quantity of API ordered by Intrexon under this Section 7.3 in any calendar quarter up to [*****] percent ([*****]%) of the quantity forecasted for the [*****] quarterly period of the most recent forecast. If Intrexon’s

  
 19 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
orders in any calendar quarter exceed [*****] percent ([*****]%) of the quantity forecasted for the [*****] quarterly period of the most recent forecast, Halozyme shall use commercially
reasonable efforts to supply such excess. Halozyme shall use commercially reasonable efforts to meet Intrexon’s delivery requirements specified in accordance with Section 7.3.4. In the event of a shortfall to forecast, Halozyme shall use
commercially reasonable efforts to apportion API among Intrexon and its other customers on a pro rata basis according to their respective forecasts. 
 7.3.4 Intrexon shall make all purchases under this Section 7.3 by submitting firm purchase orders to Halozyme. Each such purchase order shall be in writing in a form reasonably acceptable to
Halozyme, and shall specify the quantity of API ordered, the place of delivery and the required delivery date therefor, which shall not be less than [*****] days after the date of such purchase order. No additional terms of any such purchase order
shall be binding on Halozyme and are expressly rejected hereby. In the event of a conflict between the terms and conditions of any purchase order and this Agreement, the terms and conditions of this Agreement shall prevail. 

7.4 Delivery and Acceptance. 
 7.4.1 All API supplied under this Agreement shall be shipped [*****] (Incoterms 2010) [*****] to such location as designated by Intrexon. Any change in the location of manufacture or distribution shall
require the consent of Intrexon, such consent not to be unreasonably withheld or delayed. Title and risk of loss and damages to the API purchased by Intrexon hereunder shall pass to Intrexon upon receipt by the applicable carrier. 

7.4.2 Intrexon shall pay all [*****] applicable to the sale and transport of API purchased by Intrexon under this Section 7.3.4.

 7.4.3 If a shipment of API or any portion thereof is not in conformance with the API Specifications, then Intrexon shall
have the right to reject such shipment of API unless it is reasonably determinable that only a portion of the shipment fails to conform, in which case Intrexon shall have the right only to reject the portion thereof that fails to so conform.
Intrexon shall give written notice to Halozyme of its rejection hereunder, within [*****] days after Intrexon’s receipt of such shipment, specifying the grounds for such rejection. Notwithstanding the above, if the nonconformity of the API
could not have been ascertained by Intrexon upon reasonable inspection and analysis of the API, then the [*****] day period referred to herein shall not apply, provided that Intrexon notifies Halozyme promptly upon discovery of such nonconformity
(but in no event later than [*****] days from the date of the discovery). All or any part of any shipment may be held for Halozyme’s disposition, at Halozyme’s expense if found to be not in conformance with the API Specifications. Halozyme
shall use its commercially reasonable efforts to cure such rejection or replace such nonconforming shipment of API, or portion thereof, within [*****] days after receipt of notice of rejection thereof. 

  
 20 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 7.4.4 Intrexon’s grounds for rejection shall be conclusive unless Halozyme
notifies Intrexon, within [*****] days of receipt by Halozyme of the notice of rejection, that it disagrees with such grounds. In the event of such a notice by Halozyme, representative samples of the batch of API in question shall be submitted to a
mutually acceptable independent laboratory or consultant (if not a laboratory analysis issue) for analysis or review, the costs of which shall be paid by the party that is determined by the independent laboratory or consultant to have been incorrect
in its determination of whether the applicable API should be rejected. 
 7.5 [*****]. If (a) Halozyme [*****]
(b) Halozyme [*****] then Intrexon may [*****]. Within sixty (60) days after the Effective Date, Halozyme will [*****]. Notwithstanding the foregoing, (i) regardless of whether [*****], Intrexon shall [*****] [*****], Halozyme can
demonstrate to Intrexon’s reasonable satisfaction that Halozyme [*****]. 
 7.6 LIMITATION OF LIABILITY.
HALOZYME’S LIABILITY TO INTREXON, AND INTREXON’S REMEDY, UNDER SECTION 7.4.3 SHALL BE THE REJECTION AND REPLACEMENT OF NON-CONFORMING API WITH API THAT CONFORMS WITH THE TERMS AND CONDITIONS OF THIS AGREEMENT WITHIN A COMMERCIALLY
REASONABLE TIME. NOTHING IN THIS SECTION 7.6 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER ARTICLE 10. 
 7.7 Warranty. Halozyme warrants that all API delivered to Intrexon pursuant to this Agreement shall conform with the API Specifications and the certificate of analysis, shall be free from defects
in manufacturing, handling, material and workmanship, and shall be manufactured in accordance with cGMP as in effect at the time (unless the parties otherwise mutually agree) and in compliance with applicable laws and regulations. EXCEPT AS

  
 21 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, HALOZYME MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO API. HALOZYME DISCLAIMS ALL OTHER WARRANTIES, EXPRESS AND IMPLIED,
INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. NOTHING IN THIS SECTION 7.7 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY
UNDER ARTICLE 10. 
 7.8 Supply Strategy. Commencing not later than the [*****] anniversary of the Effective Date,
Halozyme shall be responsible for implementing a commercially reasonable supply strategy for API to meet Intrexon’s reasonably anticipated forecasts provided pursuant to Section 7.3. Halozyme shall review such supply strategy with Intrexon
at least [*****], and prior to implementing any material change required by a CBE-30, a Prior Approval Supplement or equivalent regulatory filing. Halozyme shall notify Intrexon of any annual reportable changes within [*****] days after their
submission to FDA. 
 7.9 Quality Agreement. The parties agree to negotiate and enter into a mutually acceptable quality
agreement relating to the supply of API hereunder. Such quality agreement shall be entered into within [*****] days of the Effective Date. 
 7.10 Supply of API After Expiration of this Agreement. During the [*****] month period before the anticipated expiration of this Agreement, and upon the written request of Intrexon, the
parties shall negotiate in good faith the terms and conditions regarding the continued supply of API by Halozyme to Intrexon. 
  

	 	8.	INTELLECTUAL PROPERTY RIGHTS. 

 8.1 Ownership of Intellectual Property. The intellectual property rights and ownership outlined in this Article 8 shall supersede the intellectual property rights and ownership terms of the
Material Transfer Agreement dated May 23, 2011 between Halozyme and Intrexon. Each party shall assist the other party in any reasonable manner to obtain, perfect and enforce the other party’s rights in any and all countries, in and to all
intellectual property as set forth below. In addition, the Parties agree to assign, or cause to be assigned, intellectual property rights in and to all intellectual property as set forth below. The Parties agree that: 

8.1.1 Intrexon shall solely own the Collaboration Supported Intrexon Biologic Patents and any unpatentable Collaboration Inventions
solely relating to the Intrexon Biologic; 
 8.1.2 Halozyme shall solely own the Collaboration Supported PH20 Patents and any
unpatentable Collaboration Inventions solely relating to the PH20 Drug; and 
 8.1.3 Intrexon and Halozyme shall jointly own
the Collaboration Supported Product Patents and any Collaboration Invention that is not a Collaboration Supported Intrexon Biologic Patent or Collaboration Supported PH20 Patent, or if unpatentable does not solely relate to the Intrexon Biologic or
does not solely relate to the PH20 Drug. 

  
 22 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 8.2 Prosecution, Maintenance and Enforcement. 

8.2.1 Intrexon shall have the first right, at its sole expense, to prepare, file, prosecute and maintain the Collaboration Supported
Product Patents. Intrexon shall give Halozyme an opportunity to review and comment on the text of each patent application included within the Collaboration Supported Product Patents before filing, shall supply Halozyme with a copy of such patent
application as filed, together with notice of its filing date and serial number, and shall give Halozyme an opportunity to review and comment on the text of all correspondence received from any patent office. Intrexon shall consider in good faith
the interests of Halozyme in the prosecution of the Collaboration Supported Product Patents. Halozyme shall assist Intrexon, upon request and at Intrexon’s sole expense, and to the extent commercially reasonable, in connection therewith. If
Intrexon elects not to file any patent application included in the Collaboration Supported Product Patents in any country, or decides to abandon any such pending application or issued patent in any country, then Intrexon shall provide written notice
to Halozyme, and Halozyme shall have the right at its sole expense to assume control of the preparation, filing, prosecution and maintenance of such patent application or patent at its own expense. 

8.2.2 Intrexon shall have the first right to enforce the Collaboration Supported Product Patents against third party infringers. With
respect to any infringement of the Collaboration Supported Product Patents by a third party, if Intrexon fails to abate such infringement or to file an action to abate such infringement within ninety (90) days after a written request from
Halozyme to do so, or if Intrexon discontinues the prosecution of any such action after filing without abating such infringement, then Halozyme shall have the right to enforce the Collaboration Supported Product Patents against such third party
infringer. With respect any action to enforce the Collaboration Supported Product Patents to abate any infringement by a third party, all monies recovered upon the final judgment or settlement of any such action shall (a) first, be used to
reimburse the costs and expenses (including reasonable attorneys’ fees and costs) of Halozyme and Intrexon; and (b) second, (i) if Intrexon brings such enforcement action, be treated as Net Sales, except for recovered punitive damages
which are to be shared equally between the parties and (ii) if Halozyme brings such enforcement action, be shared equally between the parties. 
 8.2.3 Intrexon shall have the sole right, at its sole expense, to prepare, file, prosecute, maintain and enforce the Collaboration Supported Intrexon Biologic Patents. Intrexon shall consider in good
faith the interests of Halozyme in so doing. Halozyme shall assist Intrexon, upon request and at Intrexon’s sole expense, and to the extent commercially reasonable, in connection therewith. Nothing in this Agreement grants any ownership right
in the Collaboration Supported Intrexon Biologic Patents to Halozyme, and Intrexon shall remain the sole owner of the Collaboration Supported Intrexon Biologic Patents. 
 8.2.4 Halozyme shall have the sole right, at its sole expense, to prepare, file, prosecute, maintain and enforce the Collaboration Supported PH20 Patents and Licensed Patent Rights. Halozyme shall
consider in good faith the interests of Intrexon in so doing. Intrexon shall assist Halozyme, upon request and at Halozyme’s sole expense, and to the extent commercially reasonable, in connection therewith. Nothing in this Agreement grants any
ownership right in the Collaboration Supported PH20 Patents or the Licensed Patent Rights to Intrexon, and Halozyme shall remain the sole owner of the Collaboration Supported PH20 Patents and the Licensed Patent Rights. 

  
 23 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 8.2.5 With respect to any substantial and continuing infringement of the Licensed
Patent Rights by a third party making, using, offering for sale, selling or importing a product that consists of an Exclusive Biologic combined with PH20 Drug
 ([*****]) that is directed to the Exclusive Field in a country, on a
country-by-country basis, if Halozyme fails to abate such infringement or to file an action to abate such infringement within [*****] days (or [*****] days in the case of a paragraph IV certification) after a written request from Intrexon
to do so, or if Halozyme discontinues the prosecution of any such action after filing without abating such infringement, then until such time as such infringement is abated, the royalty rate for the Product in such country shall be reduced by
[*****] of the royalty rate set forth in Section 4.4. 
 8.2.6 With respect any action to enforce the Licensed Patent
Rights to abate any infringement of the Licensed Patent Rights by a third party making, using, offering for sale, selling or importing a product that consists of an Exclusive Biologic combined with PH20 Drug ([*****]) that is directed to the
Exclusive Field in a country, all monies recovered upon the final judgment or settlement of any such action shall be used (a) first, to reimburse the costs and expenses (including reasonable attorneys’ fees and costs) of Halozyme and
Intrexon; and (b) the remainder to be shared equally between the parties. 
 8.3 Grantback License. Intrexon hereby
grants to Halozyme a perpetual, royalty-free, fully paid up, nonexclusive, worldwide license under any Grantback Patents for the purpose of developing, making, using, selling, offering for sale or importing PH20 Drug ([*****]) alone or combined with
any biologic or molecule, in each case other than (i) Products in the Licensed Field, or (ii) products that consist of an Exclusive Biologic combined with PH20 Drug ([*****]) that is directed to the Exclusive Field. Halozyme shall have the
right to grant sublicenses under such rights to any third party provided that such third party has similarly granted to Halozyme a grantback license (with the right to sublicense to Intrexon). If Halozyme is unable to obtain such a grantback license
from any such third party, then Halozyme shall not grant a sublicense to such third party under the foregoing license grant from Intrexon, and any such sublicense granted by Halozyme to such third party shall be void. For the avoidance of doubt, the
foregoing license grant shall not include rights to any molecule separate from the combination with PH20 Drug ([*****]). 
  

	 	9.	CONFIDENTIALITY. 

 9.1
Confidentiality. During the term of this Agreement and for a period of [*****] following the later of (i) the expiration or earlier termination hereof or (ii) the last commercial sale of a product developed hereunder, each party
shall maintain in confidence the Confidential Information of the other party, shall not use or grant the use of the Confidential Information of the other party except as expressly permitted hereby, and shall not disclose the Confidential Information
of the other party except on a need-to-know basis to such party’s affiliates, directors, officers, employees and consultants, to the extent such disclosure is reasonably necessary in connection with such party’s activities as expressly
authorized by this Agreement and provided that the recipient of the Confidential Information is subject to an 

  
 24 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
existing written agreement to hold in confidence and not disclose, use or grant the use of the Confidential Information of the other party except as expressly permitted under this Agreement. Each
party shall notify the other party promptly upon discovery of any unauthorized use or disclosure of the other party’s Confidential Information. Notwithstanding the foregoing, with respect to any Confidential Information that the disclosing
party deems to be a “trade secret” under applicable law, the confidentiality obligations hereunder shall continue with respect to such Confidential Information for so long as it is deemed a trade secret under applicable law. 

9.2 Terms of Agreement. Neither party shall disclose any terms or conditions of this Agreement to any third party without the
prior consent of the other party; provided, however, that a party may disclose the terms or conditions of this Agreement (a) on a need-to-know basis to its legal and financial advisors to the extent such disclosure is reasonably necessary or
(b) to a third party in connection with (i) an equity investment in such party, (ii) a merger, consolidation or similar transaction by such party, (iii) the sale of all or substantially all of the assets of such party or
(iv) a collaboration or strategic alliance relating to the subject matter of this Agreement. 
 9.3 Permitted
Disclosures. The confidentiality obligations under this Article 9 shall not apply to the extent that a party is required to disclose information by applicable law, regulation, stock exchange listing or order of a governmental agency or a
court of competent jurisdiction; provided, however, that (to the extent practicable) such party shall provide written notice thereof to the other party, consult with the other party with respect to such disclosure and provide the other party
sufficient opportunity to object to any such disclosure or to request confidential treatment thereof. 
 9.4
Publications. Either party may publish the results of its research and/or development under this Agreement in order to obtain recognition within the scientific community and to advance the state of scientific knowledge, and such publication
shall be subject to the following procedures. If a party desires to make any such publication (including any oral disclosure made without obligation of confidentiality), such party shall provide the other party with a copy of the proposed written
publication at least thirty [*****] prior to submission for publication, or an outline of such oral disclosure at least [*****] days prior to presentation. At the request of the other party, the publishing party shall remove any Confidential
Information of the other party therefrom. The other party additionally shall have the right (a) to propose modifications to the publication for patent reasons, and (b) to request a reasonable delay in publication in order to protect
patentable information. If the other party requests such a delay, the publishing party shall delay submission or presentation of the publication and shall not proceed with the written publication or the presentation without the prior written consent
of the other party, such consent not to be unreasonably withheld (provided that it would be unreasonable (x) for Intrexon to withhold consent if Intrexon’s primary reason for doing do is marketing concerns due to the Product performing
better than a Intrexon Subcutaneous Product or (y) for Halozyme to withhold consent if Halozyme’s primary reason for doing so is marketing concerns due to the Product performing worse than a Intrexon Subcutaneous Product). 

9.5 Clinical Trial Registry. Intrexon, in accordance with ClinicalTrials.gov or equivalent regulatory agency policies and
procedures, shall have the right to publish all studies, clinical trials and results thereof regarding Product (but not PH20 Drug alone) on the clinical trial registries which are maintained by or on behalf of Intrexon. 

  
 25 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

	 	10.	INDEMNIFICATION AND INSURANCE. 

 10.1 By Intrexon. Intrexon shall indemnify and hold harmless Halozyme, its Affiliates and their respective directors, officers, employees and agents, from and against all losses, liabilities,
damages and expenses, including reasonable attorneys’ fees and costs (collectively, “Liabilities”), resulting from any claims, demands, actions or other proceedings by any third party to the extent resulting from (a) the
breach of any representation, warranty or covenant by Intrexon under this Agreement; (b) the use by Intrexon, its sublicensees or their respective Affiliates of the Licensed IP Rights beyond the scope of the licenses granted herein;
(c) the manufacture, use, sale, handling or storage of Products by Intrexon, its sublicensees or their respective Affiliates, customers or end-users; or (d) the use by Intrexon, its sublicensees or their respective Affiliates of the
Confidential Information of Halozyme; provided, however, that the foregoing indemnification obligation shall not apply to the extent the applicable Liability results from clauses (a) – (d) under Section 10.2 below. 

10.2 By Halozyme. Halozyme shall indemnify and hold harmless Intrexon, its Affiliates and their directors, officers, employees and
agents, from and against all Liabilities resulting from any claims, demands, actions or other proceedings by any third party to the extent resulting from (a) the breach of any representation, warranty or covenant by Halozyme under this
Agreement; (b) the use by Halozyme, its sublicensees or their respective Affiliates of the Grantback Patents beyond the scope of the licenses granted herein; (c) the manufacture, use, sale, handling or storage of API by Halozyme or its
CMOs or other suppliers; or (d) the use by Halozyme, its sublicensees or their respective Affiliates of the Confidential Information of Intrexon; provided, however, that the foregoing indemnification obligation shall not apply to the extent the
applicable Liability results from clauses (a) – (d) under Section 10.1 above. 
 10.3 Procedure. If a
party (the “Indemnitee”) intends to claim indemnification under this Section 10.3, it shall promptly notify the other party (the “Indemnitor”) in writing of any claim, demand, action or other proceeding for
which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume the defense thereof with counsel mutually satisfactory to the parties;
provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due
to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in such proceeding. The obligations of this Section 10.3 shall not apply to amounts paid in settlement of any claim, demand,
action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the
commencement of any such action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Section 10.3. The Indemnitee, its employees and agents, shall reasonably cooperate
with the Indemnitor and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Section 10.3. 

  
 26 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 10.4 Insurance. Each party shall maintain insurance, including Commercial General
Liability, Product and Clinical Trials Liability, Workers Compensation and Employer’s Liability and Errors and Omissions Liability insurance, with respect to its activities under this Agreement regarding Products in such amount as such party
customarily maintains with respect to similar activities for its other products, but not less than the greater of (i) $[*****] each occurrence and aggregate for Commercial General Liability, Product and Clinical Trials Liability and Errors and
Omissions Liability insurance and $[*****] limit per accident /disease and a $[*****] disease policy limit Workers Compensation and Employer’s Liability or (ii) such amount as is reasonable and customary in the industry. Each party shall
maintain such insurance for so long as it continues its activities under this Agreement, and thereafter for [*****] years. Each party retains the right to insure or self-insure at its sole discretion, the above coverage. Each party shall
provide the other party [*****] days notice of any material change, cancellation or non-renewal of any required insurance under this Agreement. In the event of a material change, cancellation, or non-renewal in coverage, each party shall
replace such coverage to comply with this Agreement so that there is no lapse of coverage for any time period. 
  

	 	11.	TERM AND TERMINATION. 

11.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to this Article 11,
shall continue in effect until the later of (a) expiration of the last to expire of the Valid Claims, and (b) expiration of the last to expire Royalty Term. Upon the expiration (but not termination) of this Agreement, Intrexon shall have a
perpetual, fully paid-up, non-exclusive license under the Licensed Know-How Rights to make, have made, use, sell, offer for sale and import Products for use in the Licensed Field. 

11.2 Termination for Breach. If a party has materially breached this Agreement and such material breach shall continue for [*****]
days after written notice of such breach was provided to the breaching party by the nonbreaching party, the nonbreaching party shall have the right at its option to terminate this Agreement effective at the end of such [*****] day period.

 11.3 Termination by Intrexon. Intrexon may terminate this Agreement in whole or on a Product-by-Product basis at any
time upon [*****] days prior written notice to Halozyme. 
 11.4 Effect of Expiration or Termination. 

11.4.1 Expiration or termination of this Agreement shall be without prejudice to any rights which shall have accrued to the benefit of a
party prior to such expiration or termination. Without limiting the foregoing, Sections 2.3, 4.7, 6, 7.6, 8, 9, 10, 11.4 and 12 shall survive any expiration or termination of this Agreement. 

11.4.2 Except as otherwise expressly set forth in this Agreement, promptly upon the expiration or earlier termination of this Agreement,
each party shall return to the other party all tangible items regarding the Confidential Information of the other party and all copies thereof; provided, however, that each party shall have the right to retain one (1) copy for its legal files
for the sole purpose of determining its obligations hereunder. 

  
 27 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 11.5 Section 365(n) of the Bankruptcy Code. All rights and licenses
granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Section 101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under section 365(n) of the Bankruptcy Code. 

 

	 	12.	MISCELLANEOUS. 

 12.1
Governing Law. This Agreement shall be governed by, interpreted and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law principles thereof. 

12.2 Waiver. No waiver by a party hereto of any breach or default of any of the covenants or agreements herein set forth shall be
deemed a waiver as to any subsequent and/or similar breach or default. 
 12.3 Assignment. Neither this Agreement nor any
right or obligation hereunder may be assigned or delegated, in whole or part, by either party without the prior express written consent of the other; provided, however, that either party may, without the written consent of the other, assign this
Agreement and its rights and delegate its obligations hereunder to an Affiliate, or in connection with the transfer or sale of all or substantially all of its business related to this Agreement, or in the event of its merger, consolidation, change
in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 12.3 shall be void. 

12.4 Independent Contractors. The relationship of the parties hereto is that of independent contractors. The parties hereto are
not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the transactions contemplated thereby. 
 12.5 Further Actions. Each party shall execute, acknowledge and deliver such further documents and instruments and to perform all such other acts as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement. 
 12.6 Notices. All requests and notices required or permitted to
be given to the parties hereto shall be given in writing, shall expressly reference the section(s) of this Agreement to which they pertain, and shall be delivered to the other party, effective on receipt, at the appropriate address as set forth
below or to such other addresses as may be designated in writing by the parties from time to time during the term of this Agreement. 
  

			
	If to Halozyme:	    	Halozyme, Inc.
		    	11388 Sorrento Valley Road
		    	San Diego, California 92121
		    	Attn: Chief Executive Officer

  
 28 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

			
	If to Intrexon:	    	Intrexon Corporation
		    	20358 Seneca Meadows Pkwy
		    	Germantown, Maryland 20876
		    	Attn: Legal Department

 12.7 Force Majeure. Nonperformance of a party (other than for the payment of money) shall be
excused to the extent that performance is rendered impossible by strike, fire, earthquake, flood, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and
not caused by the negligence, intentional conduct or misconduct of the nonperforming party; provided, however, that the nonperforming party shall use commercially reasonable efforts to resume performance as soon as reasonably practicable.

 12.8 No Consequential Damages. IN NO EVENT SHALL A PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL
DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS
SECTION 12.8 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER ARTICLE 10. 
 12.9 Halozyme In-Licenses. Notwithstanding anything to the contrary in this Agreement, the grant of rights by Halozyme under this Agreement shall be subject to and limited in all respects by the
terms of the applicable Halozyme In-Licenses pursuant to which Halozyme acquired any Licensed IP Rights, and all rights or sublicenses granted under this Agreement shall be limited to the extent that Halozyme may grant such rights and sublicenses
under such Halozyme In-Licenses, in each case to the extent specifically identified on Schedule 1.26. Halozyme shall keep the Halozyme In-Licenses in full force and effect throughout the term of this Agreement. 

12.10 Complete Agreement. This Agreement, together with the Schedules hereto, constitutes the entire agreement between the parties
regarding the subject matter hereof, and all prior representations, understandings and agreements regarding the subject matter hereof, either written or oral, expressed or implied, are superseded and shall be and of no effect. 

12.11 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and together
shall be deemed to be one and the same agreement. 
 12.12 Headings. The captions to the several sections hereof are not
a part of this Agreement, but are included merely for convenience of reference only and shall not affect its meaning or interpretation. 

  
 29 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by
their duly-authorized representatives as of the Effective Date. 
  

			
	HALOZYME, INC.
		
	By:	 	 /s/ Gregory I. Frost

		
	Name:	 	 Gregory I. Frost

		
	Title:	 	 President & CEO

	
	INTREXON CORPORATION
		
	By:	 	 /s/ Gerardo Zapata

		
	Name:	 	 Gerardo Zapata

		
	Title:	 	 President Protein Production and SVP

  
 30 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 1.3 
 API Specifications 
 [*****] 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 1.26 
 Halozyme In-Licenses 
 CONFIDENTIAL 

[*****] 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 1.28 
 Intrexon Biologic 
 [*****] 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential
treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 SCHEDULE 2.2.1(a) 

Licensed Patent Rights 
 [*****] 

  
 34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]